

**Emergency Department Trends
From the
Drug Abuse Warning Network,
Preliminary Estimates January–June 2002**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Office of Applied Studies**

ACKNOWLEDGMENTS

The findings in this publication are based on data developed for the Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies (OAS), by Johnson, Bassin, and Shaw, Inc. (JBS) under Contract No. 283-98-9010 and by Westat under Contracts No. 283-02-9025 and 282-98-0003. Dr. Judy Ball (SAMHSA/OAS Project Director) and Tracy Garfield (Westat) wrote the publication. Other significant contributors at Westat include Dr. Wendy Kissin (Project Director), Jim Green, Nita Lemanski, Diane Steele, Pat Stouffer, and Lois White.

PUBLIC DOMAIN NOTICE

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from the Substance Abuse and Mental Health Services Administration (SAMHSA). However, this publication may *not* be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA. Citation of the source is appreciated. Suggested citation:

Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
Emergency Department Trends From the Drug Abuse Warning Network, Preliminary Estimates January–June 2002, DAWN Series: D-22, DHHS Publication No. (SMA) 03-3779, Rockville, MD, 2002.

OBTAINING ADDITIONAL COPIES OF PUBLICATION

Copies may be obtained, free of charge, from the National Clearinghouse for Alcohol and Drug Information (NCADI). NCADI is a service of the Substance Abuse and Mental Health Services Administration (SAMHSA). Write or call NCADI at:

National Clearinghouse for Alcohol and Drug Information (NCADI)
P.O. Box 2345, Rockville, MD 20847-2345
301-468-2600 800-729-6686 TDD 800-487-4889

ELECTRONIC ACCESS TO PUBLICATION

This publication can be accessed electronically through Internet World Wide Web connections:

<http://www.samhsa.gov>
<http://www.drugabusestatistics.samhsa.gov>
<http://www.DAWNinfo.net>

ORIGINATING OFFICE

SAMHSA, Office of Applied Studies
5600 Fishers Lane, Room 16-105
Rockville, MD 20857

December 2002

CONTENTS

Section	Page
ACKNOWLEDGMENTS	2
HIGHLIGHTS	23
INTRODUCTION.....	29
Other DAWN publications.....	30
Overview of DAWN ED component.....	30
Data collection methodology	31
Considerations when interpreting DAWN data.....	32
Interpretation of statistical significance.....	33
Other considerations when reading DAWN tables.....	34
How to use this publication.....	35
Organization of tables.....	36
Additional content available on the Internet.....	42
TRENDS IN ED DRUG EPISODES AND MAJOR SUBSTANCES OF ABUSE.....	45
TRENDS IN OTHER SUBSTANCES OF ABUSE	53
SELECTED TRENDS IN 21 METROPOLITAN AREAS	57
DISCUSSION OF RESULTS	61

LIST OF APPENDIXES

Appendix		Page
A	RACE AND ETHNICITY DATA IN DAWN.....	63
B	DETAILED DESCRIPTION OF DAWN.....	65
	Sample design	65
	Sampling weights	67
	Precision of the estimates and standards for publication	67
	Preliminary versus final estimates	69
	Estimates of rates per 100,000 population.....	70
	Revision of estimation system.....	71
C	SOURCES OF ERROR IN DAWN ESTIMATES	73
	Changes in sample composition and reporting of episodes	73
	Noteworthy sources of error: Atlanta data for 2001.....	74
D	GLOSSARY OF TERMS.....	75
	Definitions of terms common to DAWN's ED and mortality components	75
	Definitions of terms for the DAWN ED component.....	80
E	MULTUM LICENSE AGREEMENT	87
F	DAWN EMERGENCY DEPARTMENT REPORT FORM	91

CONTENTS

LIST OF TABLES

Table		Page
SAMPLING & PRECISION INFORMATION ON THE SAMPLE		
1.1	ED sample information and response rates by metropolitan area, 2001 ...	T-3
1.2	Counties and cities that constitute DAWN ED metropolitan areas, 2001 ...	T-4
1.3	ED visits, drug episodes, and drug mentions: Unweighted sample data and weighted estimates by metropolitan area, 2001	T-5
1.4	ED visits: Estimates by metropolitan area by year	T-6
1.5	ED visits: Estimated rates per 100,000 population by metropolitan area by year.....	T-7
MEASURES OF PRECISION		
1.6	ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by metropolitan area, 2001	T-8
1.7	ED drug episodes, relative standard errors, and mentions for major drugs of abuse: Estimates by metropolitan area, 2001	T-9
1.8	ED drug episodes, standard errors, relative standard errors, and confidence intervals: Estimates by drug category, 2001	T-10
1.9	Population by age and gender by metropolitan area.....	T-12
1.10	ED drug episodes by detailed race and ethnicity: Estimates for the coterminous U.S., 2001	T-15

CONTENTS

LIST OF TABLES

Table		Page
	ESTIMATES¹	
	SELECTED DRUG CATEGORIES FOR U.S. & 21 METROPOLITAN AREAS	
	ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimates	
2.1.0	Selected drug categories for the coterminous U.S. by half year <i>*2.1.1 – 2.1.21 Selected drug categories for each metropolitan area by half year</i>	T-16
2.2.0	Selected drug categories for the coterminous U.S. by year	T-18
2.2.1	Atlanta	T-20
2.2.2	Baltimore	T-22
2.2.3	Boston	T-24
2.2.4	Buffalo	T-26
2.2.5	Chicago	T-28
2.2.6	Dallas	T-30
2.2.7	Denver	T-32
2.2.8	Detroit.....	T-34
2.2.9	Los Angeles.....	T-36
2.2.10	Miami.....	T-38
2.2.11	Minneapolis	T-40
2.2.12	New Orleans.....	T-42
2.2.13	New York.....	T-44
2.2.14	Newark	T-46
2.2.15	Philadelphia.....	T-48
2.2.16	Phoenix	T-50
2.2.17	St. Louis	T-52
2.2.18	San Diego.....	T-54
2.2.19	San Francisco	T-56
2.2.20	Seattle	T-58
2.2.21	Washington, DC	T-60

¹ Relative standard error (RSE) tables corresponding to all estimate tables are published on the Internet using the same table numbers and beginning with the prefix, "RSE."

* These tables are published only on the Internet at <http://www.samhsa.gov/oas/dawn.htm> and <http://www.DAWNinfo.net>.

CONTENTS

LIST OF TABLES (continued)

Table		Page
	DETAIL OF DRUGS CONTAINED IN SELECTED DRUG CATEGORIES ED mentions by drug category: Estimates for the coterminous U.S.	
2.3.0	Selected major substances of abuse by half year <i>*2.3.1 – 2.3.21 Selected major substances of abuse for each metropolitan area by half year</i>	T-62
2.4.0	Selected major substances of abuse by year <i>*2.4.1 – 2.4.21 Selected major substances of abuse for each metropolitan area by year</i>	T-72
2.5.0	Psychotherapeutic agents by half year <i>*2.5.1 – 2.5.21 Psychotherapeutic agents for each metropolitan area by half year</i>	T-82
2.6.0	Psychotherapeutic agents by year <i>*2.6.1 – 2.6.21 Psychotherapeutic agents for each metropolitan area by year</i>	T-86
2.7.0	Central nervous system agents by half year <i>*2.7.1 – 2.7.21 Central nervous system agents for each metropolitan area by half year</i>	T-90
2.8.0	Central nervous system agents by year <i>*2.8.1 – 2.8.21 Central nervous system agents for each metropolitan area by year</i>	T-97
2.9.0	Respiratory agents by half year <i>*2.9.1 – 2.9.21 Respiratory agents for each metropolitan area by half year</i>	T-104
2.10.0	Respiratory agents by year <i>*2.10.1 – 2.10.21 Respiratory agents for each metropolitan area by year</i>	T-110
2.11.0	Cardiovascular agents by half year <i>*2.11.1 – 2.11.21 Cardiovascular agents for each metropolitan area by half year</i>	T-116
2.12.0	Cardiovascular agents by year <i>*2.12.1 – 2.12.21 Cardiovascular agents for each metropolitan area by year</i>	T-121

CONTENTS

LIST OF TABLES (continued)

Table		Page
ESTIMATES FOR THE COTERMINOUS U.S. & 21 METROPOLITAN AREAS		
ED drug episodes/mentions: Estimates by metropolitan area		
3.1	Episodes by half year	T-126
3.2	Episodes by year	T-127
3.3	Mentions by half year	T-128
3.4	Mentions by year	T-129
3.5	Alcohol-in-combination mentions by half year	T-130
3.6	Alcohol-in-combination mentions by year	T-131
3.7	Cocaine mentions by half year	T-132
3.8	Cocaine mentions by year	T-133
3.9	Heroin mentions by half year	T-134
3.10	Heroin mentions by year	T-135
3.11	Marijuana mentions by half year	T-136
3.12	Marijuana mentions by year	T-137
3.13	Amphetamines mentions by half year	T-138
3.14	Amphetamines mentions by year	T-139
3.15	Methamphetamine mentions by half year	T-140
3.16	Methamphetamine mentions by year	T-141
3.17	MDMA (Ecstasy) mentions by half year	T-142
3.18	MDMA (Ecstasy) mentions by year	T-143
3.19	Ketamine mentions by half year	T-144
3.20	Ketamine mentions by year	T-145
3.21	LSD mentions by half year	T-146
3.22	LSD mentions by year	T-147
3.23	PCP mentions by half year	T-148
3.24	PCP mentions by year	T-149
3.25	Miscellaneous hallucinogens mentions by half year	T-150
3.26	Miscellaneous hallucinogens mentions by year	T-151
3.27	Flunitrazepam (Rohypnol) mentions by half year	T-152
3.28	Flunitrazepam (Rohypnol) mentions by year	T-153
3.29	GHB mentions by half year	T-154
3.30	GHB mentions by year	T-155
3.31	Inhalants mentions by half year	T-156
3.32	Inhalants mentions by year	T-157
3.33	Combinations NTA by half year	T-158
3.34	Combinations NTA by year	T-159

CONTENTS

LIST OF TABLES (continued)

Table		Page
DEMOGRAPHIC CHARACTERISTICS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR		
ED drug episodes/mentions by patient demographic characteristics: Estimates		
4.1.0	Episodes for the coterminous U.S. by half year..... <i>*4.1.1 – 4.1.21 Episodes for each metropolitan area by half year</i>	T-160
4.2.0	Episodes for the coterminous U.S. by year.....	T-161
4.2.1	Atlanta.....	T-162
4.2.2	Baltimore.....	T-163
4.2.3	Boston.....	T-164
4.2.4	Buffalo.....	T-165
4.2.5	Chicago.....	T-166
4.2.6	Dallas.....	T-167
4.2.7	Denver.....	T-168
4.2.8	Detroit.....	T-169
4.2.9	Los Angeles.....	T-170
4.2.10	Miami.....	T-171
4.2.11	Minneapolis.....	T-172
4.2.12	New Orleans.....	T-173
4.2.13	New York.....	T-174
4.2.14	Newark.....	T-175
4.2.15	Philadelphia.....	T-176
4.2.16	Phoenix.....	T-177
4.2.17	St. Louis.....	T-178
4.2.18	San Diego.....	T-179
4.2.19	San Francisco.....	T-180
4.2.20	Seattle.....	T-181
4.2.21	Washington, DC.....	T-182
4.3.0	Mentions for the coterminous U.S. by half year..... <i>*4.3.1 – 4.3.21 Mentions for each metropolitan area by half year</i>	T-184
4.4.0	Mentions for the coterminous U.S. by year..... <i>*4.4.1 – 4.4.21 Mentions for each metropolitan area by year</i>	T-185
4.5.0	Alcohol-in-combination mentions for the coterminous U.S. by half year .. <i>*4.5.1 – 4.5.21 Alcohol-in-combination mentions for each metropolitan area by half year</i>	T-186
4.6.0	Alcohol-in-combination mentions for the coterminous U.S. by year .. <i>*4.6.1 – 4.6.21 Alcohol-in-combination mentions for each metropolitan area by year</i>	T-187

CONTENTS

LIST OF TABLES (continued)

Table		Page
4.7.0	Cocaine mentions for the coterminous U.S. by half year..... <i>*4.7.1 – 4.7.21 Cocaine mentions for each metropolitan area by half year</i>	T-188
4.8.0	Cocaine mentions for the coterminous U.S. by year..... <i>*4.8.1 – 4.8.21 Cocaine mentions for each metropolitan area by year</i>	T-189
4.9.0	Heroin mentions for the coterminous U.S. by half year <i>*4.9.1 – 4.9.21 Heroin mentions for each metropolitan area by half year</i>	T-190
4.10.0	Heroin mentions for the coterminous U.S. by year <i>*4.10.1 – 4.10.21 Heroin mentions for each metropolitan area by year</i>	T-191
4.11.0	Marijuana mentions for the coterminous U.S. by half year <i>*4.11.1 – 4.11.21 Marijuana mentions for each metropolitan area by half year</i>	T-192
4.12.0	Marijuana mentions for the coterminous U.S. by year <i>*4.12.1 – 4.12.21 Marijuana mentions for each metropolitan area by year</i>	T-193
4.13.0	Amphetamines mentions for the coterminous U.S. by half year <i>*4.13.1 – 4.13.21 Amphetamines mentions for each metropolitan area by half year</i>	T-194
4.14.0	Amphetamines mentions for the coterminous U.S. by year..... <i>*4.14.1 – 4.14.21 Amphetamines mentions for each metropolitan area by year</i>	T-195
4.15.0	Methamphetamine mentions for the coterminous U.S. by half year <i>*4.15.1 – 4.15.21 Methamphetamine mentions for each metropolitan area by half year</i>	T-196
4.16.0	Methamphetamine mentions for the coterminous U.S. by year <i>*4.16.1 – 4.16.21 Methamphetamine mentions for each metropolitan area by year</i>	T-197
4.17.0	MDMA (Ecstasy) mentions for the coterminous U.S. by half year <i>*4.17.1 – 4.17.21 MDMA (Ecstasy) mentions for each metropolitan area by half year</i>	T-198
4.18.0	MDMA (Ecstasy) mentions for the coterminous U.S. by year <i>*4.18.1 – 4.18.21 MDMA (Ecstasy) mentions for each metropolitan area by year</i>	T-199

CONTENTS

LIST OF TABLES (continued)

Table		Page
4.19.0	Ketamine mentions for the coterminous U.S. by half year..... <i>*4.19.1 – 4.19.21 Ketamine mentions for each metropolitan area by half year</i>	T-200
4.20.0	Ketamine mentions for the coterminous U.S. by year..... <i>*4.20.1 – 4.20.21 Ketamine mentions for each metropolitan area by year</i>	T-201
4.21.0	LSD mentions for the coterminous U.S. by half year..... <i>*4.21.1 – 4.21.21 LSD mentions for each metropolitan area by half year</i>	T-202
4.22.0	LSD mentions for the coterminous U.S. by year..... <i>*4.22.1 – 4.22.21 LSD mentions for each metropolitan area by year</i>	T-203
4.23.0	PCP mentions for the coterminous U.S. by half year..... <i>*4.23.1 – 4.23.21 PCP mentions for each metropolitan area by half year</i>	T-204
4.24.0	PCP mentions for the coterminous U.S. by year..... <i>*4.24.1 – 4.24.21 PCP mentions for each metropolitan area by year</i>	T-205
4.25.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by half year..... <i>*4.25.1 – 4.25.21 Miscellaneous hallucinogens mentions for each metropolitan area by half year</i>	T-206
4.26.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by year..... <i>*4.26.1 – 4.26.21 Miscellaneous hallucinogens mentions for each metropolitan area by year</i>	T-207
4.27.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by half year..... <i>*4.27.1 – 4.27.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by half year</i>	T-208
4.28.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by year ... <i>*4.28.1 – 4.28.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by year</i>	T-209
4.29.0	GHB mentions for the coterminous U.S. by half year..... <i>*4.29.1 – 4.29.21 GHB mentions for each metropolitan area by half year</i>	T-210
4.30.0	GHB mentions for the coterminous U.S. by year..... <i>*4.30.1 – 4.30.21 GHB mentions for each metropolitan area by year</i>	T-211

CONTENTS

LIST OF TABLES (continued)

Table		Page
4.31.0	Inhalants mentions for the coterminous U.S. by half year <i>*4.31.1 – 4.31.21 Inhalants mentions for each metropolitan area by half year</i>	T-212
4.32.0	Inhalants mentions for the coterminous U.S. by year <i>*4.32.1 – 4.32.21 Inhalants mentions for each metropolitan area by year</i>	T-213
4.33.0	Cominations NTA mentions for the coterminous U.S. by half year <i>*4.33.1 – 4.33.21 Combinations NTA mentions for each metropolitan area by half year</i>	T-214
4.34.0	Combinations NTA mentions for the coterminous U.S. by year <i>*4.34.1 – 4.34.21 Combinations NTA mentions for each metropolitan area by year</i>	T-215

EPISODE CHARACTERISTICS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR

ED drug episodes/mentions by episode characteristics: Estimates

5.1.0	Episodes for the coterminous U.S. by half year <i>*5.1.1 – 5.1.21 Episodes for each metropolitan area by half year</i>	T-216
5.2.0	Episodes for the coterminous U.S. by year.....	T-217
5.2.1	Atlanta.....	T-218
5.2.2	Baltimore.....	T-219
5.2.3	Boston.....	T-220
5.2.4	Buffalo.....	T-221
5.2.5	Chicago.....	T-222
5.2.6	Dallas.....	T-223
5.2.7	Denver.....	T-224
5.2.8	Detroit.....	T-225
5.2.9	Los Angeles.....	T-226
5.2.10	Miami.....	T-227
5.2.11	Minneapolis.....	T-228
5.2.12	New Orleans.....	T-229
5.2.13	New York.....	T-230
5.2.14	Newark.....	T-231
5.2.15	Philadelphia.....	T-232
5.2.16	Phoenix.....	T-233
5.2.17	St. Louis.....	T-234
5.2.18	San Diego.....	T-235
5.2.19	San Francisco.....	T-236
5.2.20	Seattle.....	T-237
5.2.21	Washington, DC.....	T-238

CONTENTS

LIST OF TABLES (continued)

Table		Page
5.3.0	Mentions for the coterminous U.S. by half year <i>*5.3.1 – 5.3.21 Mentions for each metropolitan area by half year</i>	T-240
5.4.0	Mentions for the coterminous U.S. by year..... <i>*5.4.1 – 5.4.21 Mentions for each metropolitan area by year</i>	T-241
5.5.0	Alcohol-in-combination mentions for the coterminous U.S. by half year... <i>*5.5.1 – 5.5.21 Alcohol-in-combination mentions for each metropolitan area by half year</i>	T-242
5.6.0	Alcohol-in-combination mentions for the coterminous U.S. by year <i>*5.6.1 – 5.6.21 Alcohol-in-combination mentions for each metropolitan area by year</i>	T-243
5.7.0	Cocaine mentions for the coterminous U.S. by half year..... <i>*5.7.1 – 5.7.21 Cocaine mentions for each metropolitan area by half year</i>	T-244
5.8.0	Cocaine mentions for the coterminous U.S. by year..... <i>*5.8.1 – 5.8.21 Cocaine mentions for each metropolitan area by year</i>	T-245
5.9.0	Heroin mentions for the coterminous U.S. by half year <i>*5.9.1 – 5.9.21 Heroin mentions for each metropolitan area by half year</i>	T-246
5.10.0	Heroin mentions for the coterminous U.S. by year <i>*5.10.1 – 5.10.21 Heroin mentions for each metropolitan area by year</i>	T-247
5.11.0	Marijuana mentions for the coterminous U.S. by half year <i>*5.11.1 – 5.11.21 Marijuana mentions for each metropolitan area by half year</i>	T-248
5.12.0	Marijuana mentions for the coterminous U.S. by year <i>*5.12.1 – 5.12.21 Marijuana mentions for each metropolitan area by year</i>	T-249
5.13.0	Amphetamines mentions for the coterminous U.S. by half year <i>*5.13.1 – 5.13.21 Amphetamines mentions for each metropolitan area by half year</i>	T-250
5.14.0	Amphetamines mentions for the coterminous U.S. by year..... <i>*5.14.1 – 5.14.21 Amphetamines mentions for each metropolitan area by year</i>	T-251
5.15.0	Methamphetamine mentions for the coterminous U.S. by half year <i>*5.15.1 – 5.15.21 Methamphetamine mentions for each metropolitan area by half year</i>	T-252

CONTENTS

LIST OF TABLES (continued)

Table		Page
5.16.0	Methamphetamine mentions for the coterminous U.S. by year <i>*5.16.1 – 5.16.21 Methamphetamine mentions for each metropolitan area by year</i>	T-253
5.17.0	MDMA (Ecstasy) mentions for the coterminous U.S. by half year <i>*5.17.1 – 5.17.21 MDMA (Ecstasy) mentions for each metropolitan area by half year</i>	T-254
5.18.0	MDMA (Ecstasy) mentions for the coterminous U.S. by year <i>*5.18.1 – 5.18.21 MDMA (Ecstasy) mentions for each metropolitan area by year</i>	T-255
5.19.0	Ketamine mentions for the coterminous U.S. by half year <i>*5.19.1 – 5.19.21 Ketamine mentions for each metropolitan area by half year</i>	T-256
5.20.0	Ketamine mentions for the coterminous U.S. by year <i>*5.20.1 – 5.20.21 Ketamine mentions for each metropolitan area by year</i>	T-257
5.21.0	LSD mentions for the coterminous U.S. by half year <i>*5.21.1 – 5.21.21 LSD mentions for each metropolitan area by half year</i>	T-258
5.22.0	LSD mentions for the coterminous U.S. by year <i>*5.22.1 – 5.22.21 LSD mentions for each metropolitan area by year</i>	T-259
5.23.0	PCP mentions for the coterminous U.S. by half year <i>*5.23.1 – 5.23.21 PCP mentions for each metropolitan area by half year</i>	T-260
5.24.0	PCP mentions for the coterminous U.S. by year <i>*5.24.1 – 5.24.21 PCP mentions for each metropolitan area by year</i>	T-261
5.25.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by half year <i>*5.25.1 – 5.25.21 Miscellaneous hallucinogens mentions for each metropolitan area by half year</i>	T-262
5.26.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by year <i>*5.26.1 – 5.26.21 Miscellaneous hallucinogens mentions for each metropolitan area by year</i>	T-263
5.27.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by half year <i>*5.27.1 – 5.27.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by half year</i>	T-264

CONTENTS

LIST OF TABLES (continued)

Table		Page
5.28.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by year ... <i>*5.28.1 – 5.28.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by year</i>	T-265
5.29.0	GHB mentions for the coterminous U.S. by half year <i>*5.29.1 – 5.29.21 GHB mentions for each metropolitan area by half year</i>	T-266
5.30.0	GHB mentions for the coterminous U.S. by year <i>*5.30.1 – 5.30.21 GHB mentions for each metropolitan area by year</i>	T-267
5.31.0	Inhalants mentions for the coterminous U.S. by half year <i>*5.31.1 – 5.31.21 Inhalants mentions for each metropolitan area by half year</i>	T-268
5.32.0	Inhalants mentions for the coterminous U.S. by year <i>*5.32.1 – 5.32.21 Inhalants mentions for each metropolitan area by year</i>	T-269
5.33.0	Cominations NTA mentions for the coterminous U.S. by half year <i>*5.33.1 – 5.33.21 Combinations NTA mentions for each metropolitan area by half year</i>	T-270
5.34.0	Combinations NTA mentions for the coterminous U.S. by year..... <i>*5.34.1 – 5.34.21 Combinations NTA mentions for each metropolitan area by year</i>	T-271

[Table numbers 6 through 11 have been reserved for future expansion.]

CONTENTS

LIST OF TABLES (continued)

Table		Page
RATES PER 100,000 POPULATION²		
SELECTED DRUG CATEGORY RATES FOR COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR		
ED mentions for selected drug categories, total ED drug episodes and mentions, and total ED visits: Estimated rates per 100,000 population		
12.1.0	Selected drug categories for the coterminous U.S. by half year..... <i>*12.1.1 – 12.1.21 Selected drug categories for each metropolitan area by half year</i>	T-272
12.2.0	Selected drug categories for the coterminous U.S. by year.....	T-274
12.2.1	Atlanta.....	T-276
12.2.2	Baltimore.....	T-278
12.2.3	Boston.....	T-280
12.2.4	Buffalo.....	T-282
12.2.5	Chicago.....	T-284
12.2.6	Dallas.....	T-286
12.2.7	Denver.....	T-288
12.2.8	Detroit.....	T-290
12.2.9	Los Angeles.....	T-292
12.2.10	Miami.....	T-294
12.2.11	Minneapolis.....	T-296
12.2.12	New Orleans.....	T-298
12.2.13	New York.....	T-300
12.2.14	Newark.....	T-302
12.2.15	Philadelphia.....	T-304
12.2.16	Phoenix.....	T-306
12.2.17	St. Louis.....	T-308
12.2.18	San Diego.....	T-310
12.2.19	San Francisco.....	T-312
12.2.20	Seattle.....	T-314
12.2.21	Washington, DC.....	T-316

² Relative standard errors (RSEs) are identical for estimates and rates. RSE tables corresponding to all rates tables are found on the Internet using the same table numbers, without the preceding number “1,” and beginning with the prefix, “RSE.”

CONTENTS

LIST OF TABLES (continued)

Table		Page
	DETAIL OF DRUGS CONTAINED IN SELECTED DRUG CATEGORIES ED mentions by drug category: Estimated rates per 100,000 population	
12.3.0	Selected major substances of abuse by half year <i>*12.3.1 – 12.3.21 Selected major substances of abuse for each metropolitan area by half year</i>	T-318
12.4.0	Selected major substances of abuse by year <i>*12.4.1 – 12.4.21 Selected major substances of abuse for each metropolitan area by year</i>	T-328
12.5.0	Psychotherapeutic agents by half year <i>*12.5.1 – 12.5.21 Psychotherapeutic agents for each metropolitan area by half year</i>	T-338
12.6.0	Psychotherapeutic agents by year <i>*12.6.1 – 12.6.21 Psychotherapeutic agents for each metropolitan area by year</i>	T-342
12.7.0	Central nervous system agents by half year <i>*12.7.1 – 12.7.21 Central nervous system agents for each metropolitan area by half year</i>	T-346
12.8.0	Central nervous system agents by year <i>*12.8.1 – 12.8.21 Central nervous system agents for each metropolitan area by year</i>	T-353
12.9.0	Respiratory agents by half year <i>*12.9.1 – 12.9.21 Respiratory agents for each metropolitan area by half year</i>	T-360
12.10.0	Respiratory agents by year <i>*12.10.1 – 12.10.21 Respiratory agents for each metropolitan area by year</i>	T-366
12.11.0	Cardiovascular agents by half year <i>*12.11.1 – 12.11.21 Cardiovascular agents for each metropolitan area by half year</i>	T-372
12.12.0	Cardiovascular agents by year <i>*12.12.1 – 12.12.21 Cardiovascular agents for each metropolitan area by year</i>	T-377

CONTENTS

LIST OF TABLES (continued)

Table		Page
	RATES OF MENTIONS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR	
	ED drug episodes/mentions: Estimated rates per 100,000 population by metropolitan area	
13.1	Episodes by half year	T-382
13.2	Episodes by year	T-383
13.3	Mentions by half year	T-384
13.4	Mentions by year.....	T-385
13.5	Alcohol-in-combination mentions by half year	T-386
13.6	Alcohol-in-combination mentions by year	T-387
13.7	Cocaine mentions by half year.....	T-388
13.8	Cocaine mentions by year	T-389
13.9	Heroin mentions by half year	T-390
13.10	Heroin mentions by year	T-391
13.11	Marijuana mentions by half year	T-392
13.12	Marijuana mentions by year.....	T-393
13.13	Amphetamines mentions by half year.....	T-394
13.14	Amphetamines mentions by year.....	T-395
13.15	Methamphetamine mentions by half year	T-396
13.16	Methamphetamine mentions by year.....	T-397
13.17	MDMA (Ecstasy) mentions by half year.....	T-398
13.18	MDMA (Ecstasy) mentions by year.....	T-399
13.19	Ketamine mentions by half year.....	T-400
13.20	Ketamine mentions by year	T-401
13.21	LSD mentions by half year.....	T-402
13.22	LSD mentions by year.....	T-403
13.23	PCP mentions by half year	T-404
13.24	PCP mentions by year	T-405
13.25	Miscellaneous hallucinogens mentions by half year	T-406
13.26	Miscellaneous hallucinogens mentions by year.....	T-407
13.27	Flunitrazepam (Rohypnol) mentions by half year	T-408
13.28	Flunitrazepam (Rohypnol) mentions by year	T-409
13.29	GHB mentions by half year	T-410
13.30	GHB mentions by year.....	T-411
13.31	Inhalants mentions by half year	T-412
13.32	Inhalants mentions by year	T-413
13.33	Combinations NTA by half year	T-414
13.34	Combinations NTA by year	T-415

CONTENTS

LIST OF TABLES (continued)

Table		Page
	RATES FOR DEMOGRAPHIC CHARACTERISTICS FOR THE COTERMINOUS U.S. AND 21 METROPOLITAN AREAS BY YEAR ED drug episodes/mentions by age and gender: Estimated rates per 100,000 population	
14.1.0	Episodes for the coterminous U.S. by half year..... <i>*14.1.1 – 14.1.21 Episodes for each metropolitan area by half year</i>	T-416
14.2.0	Episodes for the coterminous U.S. by year.....	T-417
14.2.1	Atlanta.....	T-418
14.2.2	Baltimore.....	T-419
14.2.3	Boston.....	T-420
14.2.4	Buffalo.....	T-421
14.2.5	Chicago.....	T-422
14.2.6	Dallas.....	T-423
14.2.7	Denver.....	T-424
14.2.8	Detroit.....	T-425
14.2.9	Los Angeles.....	T-426
14.2.10	Miami.....	T-427
14.2.11	Minneapolis.....	T-428
14.2.12	New Orleans.....	T-429
14.2.13	New York.....	T-430
14.2.14	Newark.....	T-431
14.2.15	Philadelphia.....	T-432
14.2.16	Phoenix.....	T-433
14.2.17	St. Louis.....	T-434
14.2.18	San Diego.....	T-435
14.2.19	San Francisco.....	T-436
14.2.20	Seattle.....	T-437
14.2.21	Washington, DC.....	T-438
14.3.0	Mentions for the coterminous U.S. by half year..... <i>*14.3.1 – 14.3.21 Mentions for each metropolitan area by half year</i>	T-440
14.4.0	Mentions for the coterminous U.S. by year..... <i>*14.4.1 – 14.4.21 Mentions for each metropolitan area by year</i>	T-441
14.5.0	Alcohol-in-combination mentions for the coterminous U.S. by half year... <i>*14.5.1 – 14.5.21 Alcohol-in-combination mentions for each metropolitan area by half year</i>	T-442
14.6.0	Alcohol-in-combination mentions for the coterminous U.S. by year..... <i>*14.6.1 – 14.6.21 Alcohol-in-combination mentions for each metropolitan area by year</i>	T-443

CONTENTS

LIST OF TABLES (continued)

Table		Page
14.7.0	Cocaine mentions for the coterminous U.S. by half year <i>*14.7.1 – 14.7.21 Cocaine mentions for each metropolitan area by half year</i>	T-444
14.8.0	Cocaine mentions for the coterminous U.S. by year <i>*14.8.1 – 14.8.21 Cocaine mentions for each metropolitan area by year</i>	T-445
14.9.0	Heroin mentions for the coterminous U.S. by half year <i>*14.9.1 – 14.9.21 Heroin mentions for each metropolitan area by half year</i>	T-446
14.10.0	Heroin mentions for the coterminous U.S. by year <i>*14.10.1 – 14.10.21 Heroin mentions for each metropolitan area by year</i>	T-447
14.11.0	Marijuana mentions for the coterminous U.S. by half year <i>*14.11.1 – 14.11.21 Marijuana mentions for each metropolitan area by half year</i>	T-448
14.12.0	Marijuana mentions for the coterminous U.S. by year <i>*14.12.1 – 14.12.21 Marijuana mentions for each metropolitan area by year</i>	T-449
14.13.0	Amphetamines mentions for the coterminous U.S. by half year <i>*14.13.1 – 14.13.21 Amphetamines mentions for each metropolitan area by half year</i>	T-450
14.14.0	Amphetamines mentions for the coterminous U.S. by year <i>*14.14.1 – 14.14.21 Amphetamines mentions for each metropolitan area by year</i>	T-451
14.15.0	Methamphetamine mentions for the coterminous U.S. by half year <i>*14.15.1 – 14.15.21 Methamphetamine mentions for each metropolitan area by half year</i>	T-452
14.16.0	Methamphetamine mentions for the coterminous U.S. by year <i>*14.16.1 – 14.16.21 Methamphetamine mentions for each metropolitan area by year</i>	T-453
14.17.0	MDMA (Ecstasy) mentions for the coterminous U.S. by half year <i>*14.17.1 – 14.17.21 MDMA (Ecstasy) mentions for each metropolitan area by half year</i>	T-454
14.18.0	MDMA (Ecstasy) mentions for the coterminous U.S. by year <i>*14.18.1 – 14.18.21 MDMA (Ecstasy) mentions for each metropolitan area by year</i>	T-455

CONTENTS

LIST OF TABLES (continued)

Table		Page
14.19.0	Ketamine mentions for the coterminous U.S. by half year..... <i>*14.19.1 – 14.19.21 Ketamine mentions for each metropolitan area by half year</i>	T-456
14.20.0	Ketamine mentions for the coterminous U.S. by year..... <i>*14.20.1 – 14.20.21 Ketamine mentions for each metropolitan area by year</i>	T-457
14.21.0	LSD mentions for the coterminous U.S. by half year..... <i>*14.21.1 – 14.21.21 LSD mentions for each metropolitan area by half year</i>	T-458
14.22.0	LSD mentions for the coterminous U.S. by year..... <i>*14.22.1 – 14.22.21 LSD mentions for each metropolitan area by year</i>	T-459
14.23.0	PCP mentions for the coterminous U.S. by half year..... <i>*14.23.1 – 14.23.21 PCP mentions for each metropolitan area by half year</i>	T-460
14.24.0	PCP mentions for the coterminous U.S. by year..... <i>*14.24.1 – 14.24.21 PCP mentions for each metropolitan area by year</i>	T-461
14.25.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by half year..... <i>*14.25.1 – 14.25.21 Miscellaneous hallucinogens mentions for each metropolitan area by half year</i>	T-462
14.26.0	Miscellaneous hallucinogens mentions for the coterminous U.S. by year..... <i>*14.26.1 – 14.26.21 Miscellaneous hallucinogens mentions for each metropolitan area by year</i>	T-463
14.27.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by half year..... <i>*14.27.1 – 14.27.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by half year</i>	T-464
14.28.0	Flunitrazepam (Rohypnol) mentions for the coterminous U.S. by year ... <i>*14.28.1 – 14.28.21 Flunitrazepam (Rohypnol) mentions for each metropolitan area by year</i>	T-465
14.29.0	GHB mentions for the coterminous U.S. by half year..... <i>*14.29.1 – 14.29.21 GHB mentions for each metropolitan area by half year</i>	T-466

CONTENTS

LIST OF TABLES (continued)

Table		Page
14.30.0	GHB mentions for the coterminous U.S. by year <i>*14.30.1 – 14.30.21 GHB mentions for each metropolitan area by year</i>	T-467
14.31.0	Inhalants mentions for the coterminous U.S. by half year <i>*14.31.1 – 14.31.21 Inhalants mentions for each metropolitan area by half year</i>	T-468
14.32.0	Inhalants mentions for the coterminous U.S. by year <i>*14.32.1 – 14.32.21 Inhalants mentions for each metropolitan area by year</i>	T-469
14.33.0	Cominations NTA mentions for the coterminous U.S. by half year <i>*14.33.1 – 14.33.21 Combinations NTA mentions for each metropolitan area by half year</i>	T-470
14.34.0	Combinations NTA mentions for the coterminous U.S. by year <i>*14.34.1 – 14.34.21 Combinations NTA mentions for each metropolitan area by year</i>	T-471

LIST OF FIGURES

Figure		Page
1	Relative standard errors (RSEs) for drug-related episodes by metropolitan area: January-June 2002.....	43
2	Tables in <i>ED Trends From DAWN</i>	43
3	ED drug-related episodes and alcohol-in-combination, cocaine, heroin, and marijuana mentions: July-December 1997 through January-June 2002.....	51
4	Relative standard errors (RSEs) for major substances of abuse: January-June 2002	51
5	ED mentions of selected narcotic analgesics: July-December 1997 through January-June 2002	56

HIGHLIGHTS

This issue of *Emergency Department Trends From DAWN* presents for the first time preliminary estimates for January to June of 2002, with comparisons to the same months of 2001.

The Drug Abuse Warning Network (DAWN) relies on a sample of hospitals operating 24-hour emergency departments (EDs) to capture data on ED visits induced by or related to substance abuse. DAWN data do not measure prevalence of drug use in the population, but the probability sample of hospitals is designed to produce representative estimates of ED drug episodes and drug mentions for the coterminous United States and for 21 metropolitan areas. The Substance Abuse and Mental Health Services Administration (SAMHSA), the agency responsible for DAWN, is required under Section 505 of the Public Health Service Act to collect such data.

Findings are statistically significant unless stated otherwise. Estimates for the first half of 2002 are preliminary, so there is no guarantee that statistically significant differences will remain once the data are complete and estimates for the full year are produced. Final estimates from 1994 to 2001 are provided for reference.

This publication (text and tables), additional tables grouped by metropolitan area, and tables of relative standard errors are available online at <http://www.samhsa.gov/oas/dawn.htm> and <http://www.DAWNinfo.net>.

TOTAL DRUG-RELATED ED EPISODES

- From January through June 2002, DAWN estimates that there were 308,558 drug abuse-related ED episodes in the coterminous U.S. with 564,196 drug mentions (on average, 1.8 drugs per episode) (Table 2.1.0). There was no statistically significant difference between the first half of 2001 and the first half of 2002 in total drug-related ED episodes or ED drug mentions (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, none of the 21 metropolitan areas oversampled in DAWN had increases in drug abuse episodes, but there were significant decreases in drug episodes in 4 metropolitan areas (Table 3.1): Seattle (-54%, from 5,720 to 2,656 episodes), Dallas (-22%, from 3,369 to 2,638), Chicago (-16%, from 16,526 to 13,937), and San Diego (-12%, from 3,615 to 3,194).

Drug Episodes vs. Drug Mentions

Drug Episode: A drug-related ED episode is an ED visit that was induced by or related to the use of an illegal drug(s) or the nonmedical use of a legal drug for patients age 6 to 97 years.

Drug Mention: A drug mention refers to a substance that was recorded (“mentioned”) during a drug-related ED episode. Because up to 4 drugs (and alcohol) can be reported for each drug abuse episode, there are more mentions than episodes cited in this report.

MAJOR SUBSTANCES OF ABUSE

- For illicit drugs, a comparison of the first half of 2001 and the first half of 2002 revealed that (Table 2.1.0):
 - There were no significant changes in ED mentions of cocaine, heroin, marijuana, amphetamines, methamphetamine, MDMA (Ecstasy), Ketamine, PCP, GHB, or inhalants.
 - LSD mentions decreased 78 percent (from 1,882 mentions in the first half of 2001 to 407 mentions in the first half of 2002).

Patient Demographics

- Total drug-related ED episodes and mentions of alcohol-in-combination, cocaine, marijuana, amphetamines, methamphetamine, MDMA (Ecstasy), Ketamine, PCP, and GHB were stable across demographic categories from the first half of 2001 to the first half of 2002 (Tables 4.1.0 through 4.33.0).
- Mentions of heroin declined 18 percent (from 14,924 in the first half of 2001 to 12,260 in the first half of 2002) among patients who were black (Table 4.9.0), and mentions of LSD declined across most demographic subgroups: both genders, white and black patients, and patients age 20 and over (Table 4.21.0).

Characteristics of ED Episodes

- Characteristics of drug-related ED episodes overall were unchanged from the first half of 2001 to the first half of 2002 (Table 5.1.0). During the first half of 2002:
 - More than half (55%) of drug-related ED episodes involved multiple drugs.
 - The motive for drug abuse was cited as dependence in more than one-third (37%), suicide in another 29 percent, and psychic effects in 20 percent of episodes. Motive was unrecorded in 13 percent of episodes.
 - The reason for the ED visit was overdose in 40 percent, unexpected reaction in 18 percent, and seeking detoxification in 17 percent of drug-related episodes. Reason for contact was unrecorded in 5 percent of episodes.
 - Patients were admitted to the hospital (49%) and treated and released (48%) in nearly equal proportions.

ALCOHOL-IN-COMBINATION

Alcohol is reportable to DAWN only when present in combination with another reportable drug.

- In the first half of 2002, alcohol-in-combination was mentioned in 32 percent of ED drug episodes (97,527 mentions). Overall, mentions of alcohol-in-combination were statistically unchanged from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- Mentions of alcohol-in-combination increased 56 percent (from 804 to 1,252) in Buffalo from the first half of 2001 to the first half of 2002. Significant decreases during this time period were found in Seattle (-46%, from 1,469 to 800 mentions), San Francisco (-29%, from 1,010 to 717), Dallas (-28%, from 934 to 670), and Phoenix (-23%, from 1,296 to 1,004) (Table 3.5).

COCAINE

- Nationwide, there were 91,687 ED mentions of cocaine in the first half of 2002 (Table 2.1.0). Cocaine mentions remained stable from the first half of 2001 to the first half of 2002.
- From the first half of 2001 to the first half of 2002, significant increases in cocaine mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.7): Minneapolis (47%, from 462 to 681 mentions) and Denver (47%, from 631 to 926). Significant decreases in cocaine mentions were found in 7 metropolitan areas: Seattle (-67%, from 1,660 to 551), Dallas (-32%, from 964 to 654), Detroit (-32%, from 4,160 to 2,820), Washington, DC (-28%, from 1,440 to 1,032), San Francisco (-21%, from 1,220 to 964), Chicago (-20%, from 8,269 to 6,614), and San Diego (-11%, from 439 to 389).

HEROIN

- There were 42,571 ED mentions of heroin in the first half of 2002 (Table 2.1.0). Nationwide, mentions of heroin were statistically unchanged from the first half of 2001.
- From the first half of 2001 to the first half of 2002, significant increases in heroin mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.9): Buffalo (71%, from 283 to 484 mentions) and Denver (37%, from 380 to 519). Significant decreases in heroin mentions were found in 7 metropolitan areas: Seattle (-47%, from 903 to 475 mentions), Washington, DC (-42%, from 1,024 to 591), Dallas (-41%, from 251 to 147), Detroit (-32%, from 2,102 to 1,440), Baltimore (-24%, from 2,593 to 1,977), San Diego (-21%, from 401 to 316), and Phoenix (-20%, from 372 to 298).

MARIJUANA

- There were 55,727 ED mentions of marijuana in the first half of 2002 (Table 2.1.0). Nationwide, marijuana mentions remained statistically unchanged from the first half of 2001 to the first half of 2002.
- From the first half of 2001 to the first half of 2002, significant increases in marijuana mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.11): Miami (30%, from 920 to 1,195 mentions) and San Diego (20%, from 521 to 625). Significant decreases in marijuana mentions were found in 4 metropolitan areas oversampled in DAWN (Table 3.11): Seattle (-65%, from 858 to 298), Buffalo (-49%, from 374 to 192), San Francisco (-44%, from 387 to 217), and Dallas (-36%, from 570 to 364).

AMPHETAMINES AND METHAMPHETAMINE

- In the first half of 2002, DAWN estimates 10,079 ED mentions of amphetamines and 6,136 ED mentions of methamphetamine in the coterminous U.S. (Tables 2.1.0 and 12.1.0). From the first half of 2001 to the first half of 2002, no significant change was evident for ED mentions of amphetamines or methamphetamine.
- From the first half of 2001 to the first half of 2002 (Tables 3.13 and 3.15):
 - Significant increases in mentions of amphetamines were found in 2 metropolitan areas: Denver (57%, from 163 to 256 mentions) and San Diego (31%, from 432 to 566).
 - Mentions of amphetamines decreased in 4 metropolitan areas: Seattle (-70%, from 345 to 104), Philadelphia (-45%, from 228 to 126), San Francisco (-26%, from 376 to 279), and Dallas (-24%, from 187 to 143).
 - Of the metropolitan areas with at least 100 mentions of methamphetamine, there were significant decreases in Seattle (-31%, from 166 to 115 mentions) and San Diego (-25%, from 344 to 257), and there were no significant increases.

OTHER SUBSTANCES OF ABUSE

Not all cases involving prescription or over-the-counter (OTC) drugs are reportable to DAWN. However, DAWN receives reports of ED episodes involving the nonmedical use of legal drugs. These can involve deliberate abuse of prescribed or legally obtained OTC medications or of pharmaceuticals diverted for abuse. Accidental overdoses or ingestions with no intent of abuse, or adverse reactions to OTC or prescription drugs taken as directed are not reportable to DAWN unless they were present in combination with an illicit drug. Only generic drug names are presented in DAWN publications. DAWN estimates should not be attributed to drugs marketed under particular brand (trade) names.

- DAWN estimates that other substances of abuse (251,015 mentions) accounted for 44 percent of total ED drug mentions in the first half of 2002 (Table 2.1.0). Although the vast majority of these other substances are marketed legally by prescription or over the

counter, it is impossible to know from DAWN the number of ED visits related to the abuse of prescription drugs by the person for whom the drug was prescribed for a therapeutic purpose.

- ED mentions of other substances of abuse in the first half of 2002 were most concentrated among psychotherapeutic agents (104,687 mentions) and central nervous system (CNS) agents (108,081) in nearly equal proportions (19% of total ED mentions each) (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, mentions of psychotherapeutic agents overall were stable, as were mentions for the subcategories of psychotherapeutic agents (antidepressants; antipsychotics; anxiolytics, sedatives, and hypnotics; and CNS stimulants).
- ED mentions of CNS agents overall were stable from the first half of 2001 to the first half of 2002. However, among the subcategories of CNS agents:
 - Mentions of narcotic analgesics/combinations increased 16 percent (from 47,683 to 55,311 mentions),
 - Mentions of miscellaneous analgesics/combinations decreased 17 percent (from 21,447 to 17,849 mentions), and
 - Mentions of anorexiant increased 171 percent (from 383 to 1,038).
- Among the most frequently mentioned narcotic analgesics/combinations (Table 2.7.0):
 - Estimates for codeine/combinations (2,317 mentions in the first half of 2002), hydrocodone/combinations (12,033 mentions), morphine/combinations (1,122 mentions), and propoxyphene/combinations (2,486 mentions) were stable from the first half of 2001 to the first half of 2002, as were mentions of unnamed narcotic analgesics (NOS, 18,970 mentions) and of methadone (5,190 mentions).
 - ED mentions for the category of oxycodone/combinations were not statistically changed from the first half of 2001 to the first half of 2002. However, mentions of oxycodone specifically rose significantly from the first half of 2001 to the first half of 2002 (a 59% increase, from 4,940 to 7,828 mentions).

INTRODUCTION

This publication presents estimates of drug-related emergency department (ED) visits from the Drug Abuse Warning Network (DAWN) from 1994 through the first half of 2002.

Special attention is given to the preliminary estimates for the first half of 2002, which are being released for the first time. DAWN is an ongoing, national data system that collects information on drug-related visits to EDs from a national probability sample of hospitals. The Office of Applied Studies (OAS) of the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services has been responsible for DAWN operations since 1992.

ED Trends From DAWN is published twice each year. Once each year, *ED Trends* publishes a limited set of preliminary estimates developed from the first half-year of data (i.e., January through June). Each year, a second issue of *ED Trends* presents final estimates for the most recent full year and comparisons to previous years.³ The revised estimates in the *ED Trends From DAWN* series replace those DAWN estimates published previously for 1994 through 2000.

This publication contains the following estimates of drug-related ED episodes and specific drug mentions:

- Preliminary estimates for January–June 2002, with half-year estimates from July 1997 through December 2001 for comparison.

Estimates for January–June 2002 are considered preliminary because some hospitals can be expected to report late and the sampling weights used to derive national and metropolitan area estimates for this period are not final (see Appendix B).

- Final estimates for the full years 1994 through 2001, which were published previously and are provided here for reference.

DAWN relies on a detailed “drug vocabulary” to categorize the thousands of substances that are reported each year. The drug vocabulary is, literally, the language—the codes and terminology—that DAWN uses to record and classify drugs and other substances collected from EDs. In 2001, it was necessary to implement substantial changes to the existing vocabulary to ensure that reported substances are accurately and consistently classified. The overhaul and replacement of the DAWN drug vocabulary as well as the first publication of the revised trends are described in detail in *Emergency Department Trends From the Drug Abuse Warning Network Preliminary Estimates, January–June 2001 with Revised Estimates 1994–2000*.⁴ In addition, a separate publication focusing exclusively on the drug vocabulary is forthcoming.

³ The publication series entitled *ED Trends From DAWN* replaced 2 semi-annual publications—*Mid-year Preliminary Emergency Department Data from DAWN* and *Year-end Emergency Department Data from DAWN*. It also replaced the trend tables (chapter 4) from the annual *Detailed ED Tables* prior to 2001, which are published exclusively on the Internet. (Prior to 1998, *Detailed ED Tables* were published under the title *DAWN Annual Emergency Department Data*.)

⁴ The classification of drugs currently in use by DAWN is derived from the Multum *Lexicon*, Copyright © 2001, Multum Information Services, Inc. The classification has been modified to meet DAWN's unique requirements (2001). The Multum Licensing Agreement governing use of the *Lexicon* is provided in Appendix E to this report and can be found on the Internet at <http://www.multum.com/>.

In the next section, we describe the sources and methods used to collect data for DAWN, and then highlight certain limitations of the data. Finally, we provide an overview of the layout of this publication, including a detailed description of each table and its proper interpretation.

OTHER DAWN PUBLICATIONS

The DAWN system also collects data on drug-related deaths from a nonrandom set of death investigation jurisdictions. Findings from DAWN mortality data are published annually in a separate publication series entitled *Mortality Data From the Drug Abuse Warning Network*.⁵

A relatively new series called *The DAWN Report* focuses on topics of special interest in a brief publication format.⁶ The inaugural issue of *The DAWN Report* (12/2000) focused on club drugs, a topic chosen because of the large volume of requests for information on this emerging drug problem. This issue was recently updated with estimates through 2001 (10/2002). The second issue of *The DAWN Report* featured major drugs of abuse in ED visits, which displayed the geographic distribution of cocaine, heroin, marijuana, and methamphetamine mentions on a U.S. map (7/2001). This was recently updated with estimates from 2001 as well (10/2002). Several new issues of *The DAWN Report* are scheduled for release in the near future.

OAS receives many requests for specific information from potential and actual consumers of information from DAWN. We view these requests as expressions of the need to improve the content of DAWN publications. Topics for *The DAWN Report* and modifications to other DAWN publications are often the result of consumer input.

OVERVIEW OF DAWN ED COMPONENT

The DAWN system provides information on some of the health consequences of drug abuse in the United States as manifested by drug-related visits to hospital EDs. Hospitals eligible for DAWN are non-Federal, short-stay, general medical and surgical hospitals that operate 24-hour, 7-day EDs. Since 1988, DAWN ED data have been collected from a representative sample of eligible hospitals located throughout the coterminous U.S., with oversampling in 21 metropolitan areas and a National Panel of hospitals sampled from locations outside these areas.

In 2001, the DAWN sample consisted of 564 eligible hospitals.⁷ Of these, 458 (81%) participated in DAWN. Response rates in the 21 metropolitan areas ranged from 58 percent to 100 percent, with only 2 metropolitan areas having response rates below 75 percent (Table 1.1). The 2001 sample of hospitals submitted data on 196,268 drug abuse episodes with an average of 1.8 drug mentions per episode (Table 1.3).

In the first half of 2002, 14 metropolitan areas had response rates lower than 70 percent, with the lowest at 49 percent. One of the reasons that estimates from the first half of 2002 are considered preliminary is that additional data from this period are expected and will be

⁵ For mortality data prior to 2000, the publication series was titled *Drug Abuse Warning Network Annual Medical Examiner Data*.

⁶ Issues of *The DAWN Report* are available on-line at <http://www.samhsa.gov/oas/dawn.htm> and <http://www.DAWNinfo.net>.

⁷ The DAWN sample is updated annually, so 2001 is the last full year for which the sample was drawn. The sample for 2002 will be updated at the close of the 2002 data year.

incorporated before 2002 estimates are finalized. Estimates for the first half (January–June) of 2002 will be updated upon the close of the 2002 data year.

For this publication, sampling weights have been applied to data from the sample to produce estimates representing all ED drug episodes and drug mentions in the total coterminous U.S.⁸ and in the 21 metropolitan areas (see Appendix B). The National Panel represents hospitals outside of the 21 metropolitan areas. Estimates for the 21 metropolitan areas are pooled with estimates from the National Panel to produce the national estimates. To account for differences in population and to facilitate comparisons across metropolitan areas, estimated rates of ED drug episodes and mentions per 100,000 population also are presented (see Appendix B). Population estimates used to derive the estimated rates for 2001 are presented in Table 1.9 for each DAWN metropolitan area.

DATA COLLECTION METHODOLOGY

Within each hospital that participates in DAWN, a designated DAWN reporter, who is usually a member of the ED or medical records staff, is responsible for reviewing medical charts to identify ED visits that are eligible for submission to DAWN. DAWN reporters rely on information from medical charts that originates with hospital staff who treated the patient. Ultimately, the accuracy and completeness of the data submitted to DAWN depend on the careful recording of information by the medical staff and on the accuracy and completeness of the information provided to the medical staff by the patient.

The DAWN reporter submits an episode report to the DAWN system for each patient who visits a DAWN ED and meets certain criteria. To be included in DAWN, the patient presenting to the ED must meet all of the following criteria:

- The patient was age 6 to 97;
- The patient was treated in the hospital's ED;
- The patient's presenting problem(s) (i.e., the reason for the ED visit) was induced by or related to drug use, regardless of when the drug use occurred;
- The episode involved the use of an illegal drug or the use of a legal drug or other chemical substance for nonmedical purposes; and
- The patient's reason for using the substance(s) was dependence, suicide attempt or gesture, and/or psychic effects.

In addition to drug overdoses, reportable ED episodes may result from the chronic effects of habitual drug use or from unexpected reactions. Unexpected reactions reflect cases where the drug's effect was different than anticipated (e.g., caused hallucinations). DAWN cases do **not** include accidental ingestion or inhalation of a substance with no intent of abuse, or adverse reactions to prescription or over-the-counter medications taken as prescribed.

A single drug abuse episode may have multiple drug mentions. Up to 4 different substances can be recorded for each ED episode. Therefore, not every reported substance is,

⁸ The total coterminous U.S. consists of the 48 contiguous states and the District of Columbia. Alaska and Hawaii are excluded.

by itself, necessarily a cause of the medical emergency. On the other hand, substances that contributed to a drug abuse episode may occasionally go unreported or undetected. Even when only one substance is reported for an episode, an allowance should be made for reportable drugs not mentioned or for other contributory factors.

Alcohol use is reported to DAWN **only** when alcohol is present in combination with a reportable substance.

In addition, each report of a drug-related ED episode includes demographic information about the patient and information about the circumstances of the episode (e.g., the date and time of the ED visit, the reason the patient came to the ED). Only one reason for the ED contact and one reason for taking substances are recorded, regardless of the number of substances involved.⁹

CONSIDERATIONS WHEN INTERPRETING DAWN DATA

When interpreting findings from this publication, the reader needs to recognize what DAWN can and cannot measure. DAWN does not measure the frequency or prevalence of drug use in the population, but rather the health consequences of drug use that are reflected in visits to hospital EDs. Moreover, estimates of drug episodes and mentions may increase or decrease for reasons unrelated to the size or characteristics of the drug-using population. The reader should consider the following when interpreting estimates from DAWN:

- The number of ED episodes reported to DAWN is not equivalent to the number of individual patients, because one person may make repeated visits to an ED. DAWN data contain no individual identifiers, which would be required to estimate repeat visits. Therefore, the estimates presented in this publication pertain to total ED episodes or drug mentions, not to the number of different patients involved. In this context, rates should be regarded not as prevalence rates for the population using EDs, but as indicators of the number of ED drug abuse episodes or mentions per 100,000 population.
- DAWN data may be affected by data collection procedures and thereby reflect changes in hospital services or operations. A hospital in one city may open a new detoxification unit that diverts drug-related episodes away from the ED. Conversely, in another city, people may go to the ED to seek care for detoxification because they are unable to gain admission to a drug treatment facility or because they need medical certification before entering treatment. These factors may vary over time and place.
- Estimates of drug-related ED episodes or mentions may be affected by reporting patterns. For example, a change to computer-based recordkeeping systems in a hospital ED could increase or decrease the number of ED visits identified as drug related.
- Greater awareness and knowledge of drug-related problems may result in a greater propensity for ED staff to record drug use in the ED record. Alternatively, the

⁹ For each drug mentioned, the DAWN reporting form also includes the form in which the drug was acquired (e.g., liquid, pieces), its source (e.g., street buy, patient's own legal prescription), and its route of administration (e.g., oral, injection). However, these data items frequently are unavailable from source records.

sensitivity of drug-related problems may reduce patients' willingness to disclose drug use and providers' willingness to record it in the permanent medical record.

- Estimates of drug-related ED episodes or mentions can be affected if the weights applied to the data change in an irregular way. We use a set of quality control procedures to identify and investigate unusual weights and data, and our review of the weights and data used in this publication did not reveal any factors that are unduly responsible for the trends reported.
- Trends may be affected by unusual changes in the sample composition. See Appendix B for more information regarding sampling.
- Graphs illustrating trends in drug mentions often use different scales for the vertical axis.
- The DAWN estimates beginning with 2001 utilize population data from the 2000 decennial Census. The U.S. Bureau of the Census is the source for all the population data used to produce the estimated rates (see Appendix B). It is important to note that the population denominator used to calculate rates per 100,000 population is considerably larger for 2001 due to the availability of 2000 decennial Census data. (Estimates for periods prior to 2001 used estimated yearly adjustments from the 1990 Census.) Many large decreases in 2001 population-based rates are attributable to the larger denominator. Therefore, it is important to verify reductions in rates against total estimates for the same measures. It is possible, for example, to have an estimate (in mentions or episodes) increase from 2000 to 2001 and to have the corresponding rate decrease because of changes in the population denominator. To assist the reader, the percent change columns in the rate tables are calculated based on the rates in this issue of *ED Trends*.¹⁰

INTERPRETATION OF STATISTICAL SIGNIFICANCE

The estimates of episodes and mentions displayed in tables in this publication are accompanied by columns indicating the percent change from one period to another. The percent change is indicated only for statistically significant differences and only when both estimates in the comparison are greater than zero. Although estimates in the tables are presented rounded to the nearest whole number, the percent change is calculated based on the actual, non-rounded number. In describing statistically significant differences between DAWN estimates, the traditional level of statistical significance (p less than 0.05) is used.

In tables presenting full years, the estimates for the latest year (2001) are compared to the earliest year presented in the trend (1994 in this publication), and then to the 2 previous years (1999 and 2000).

In tables presenting estimates for half years, the first half of 2002 is compared to the second half of 2001, then the first halves of 2002 and 2001 are compared. Comparisons between the second half of one year and the first half of another may be problematic because of the potential for seasonal distortions. Discussions of half-year findings in this publication will be

¹⁰ Previously (in *ED Trends From the Drug Abuse Warning Network, Preliminary Estimates January–June 2001 with Revised Estimates 1994–2000*), the percent change columns presented in the rate tables reflected the changes for the underlying estimates (mentions or episodes).

limited because the estimates for 2002 are preliminary and will focus on comparisons between the first halves of 2001 and 2002.

Each table of estimates has a corresponding table containing relative standard errors (RSEs) for each estimate, and all the p -values, including those that are 0.05 or greater, for the comparisons described above. If a p -value has a negative sign in front of it, this means that there was a decrease in the estimate between the periods noted. The RSE tables are published on the Internet. The RSE values for total estimates and rates per 100,000 population are similar, so a single RSE table is provided for each pair of estimate tables. For example, Table RSE-2.2.0 presents RSEs applicable to the estimates in Table 2.2.0 and to the estimated rates in Table 12.2.0. The statistical tests used to determine the significance levels are t -tests (with infinite degrees of freedom). That is, the change score, or the difference between the 2 estimates, is divided by the standard error of the estimate. A value of zero is expected under the null hypothesis.

Although tests for statistical significance are important tools in interpreting results, significance does not always imply that the difference is large or important. Small changes that are statistically significant may occur frequently at the metropolitan area level in DAWN due to the selection of all eligible hospitals (which constitutes a census) in Baltimore, Buffalo, Denver, San Diego, and San Francisco, along with sampling many other metropolitan areas at a high frequency (Table 1.1). The closer the sample is to a census, the higher is the likelihood that a change will be statistically significant, no matter how small it may be. While technically there is no sampling variability in the 5 areas noted, some variability is due to the hospitals' nonresponse, which is treated as sampling error in the variance calculations.

RSEs for the coterminous U.S. and for each metropolitan area are summarized in Figure 1. The RSE for total drug-related ED episodes for the coterminous U.S. is 8 percent. Across the 21 metropolitan areas oversampled in DAWN, RSEs range from a low of 3 percent in San Diego to a high of 23 percent in Los Angeles and Newark. RSEs for particular drugs are often much higher.

Nonsampling errors such as nonresponse and reporting errors may affect the outcome of significance tests. While p less than 0.05 significance level is used to determine statistical significance in DAWN ED tabulations, large differences associated with slightly higher p -values (specifically those between 0.05 and 0.10) may be of interest also. On the other hand, statistically significant differences are not always meaningful, because the size of the difference is small or because the significance may have occurred simply by chance. In a series of 20 independent tests, it is to be expected that one test will indicate a significant difference merely by chance even if there is no real difference in the populations compared. The text often discusses more than one comparison within a given table (e.g., comparing percentages for different drugs or subgroups). We have made no attempt to adjust the level of significance to account for these multiple comparisons. Therefore, the probability of falsely rejecting the null hypothesis at least once in a family of comparisons is higher than the significance level given for individual comparisons (in this publication, 0.05).

OTHER CONSIDERATIONS WHEN READING DAWN TABLES

Estimates with RSEs of 50 percent or higher are regarded as too imprecise for publication. In the tables, the symbol “...” (3 dots) has been substituted for estimates that did not meet this

standard of precision. With an RSE of 50 percent, the 95 percent confidence interval for an estimate ranges from 2 to 198 percent of the estimate's value (see Appendix B).

Similarly, some 2001 estimates for the Atlanta metropolitan area are suppressed (indicated by the symbol "---") because they are based on insufficient data (see Appendix C).

Beginning with the 1999 ED data, estimates smaller than 10 were no longer suppressed in DAWN ED publications. Many estimates as small as this are suppressed by virtue of having RSEs greater than 50 percent. For those that are shown in the tables, we note for the reader that small numbers and their associated RSEs should be interpreted with caution.

As described in Appendix B, the DAWN ED data for 1995 through 1997 were reweighted and reprogrammed, and the presentation of findings was improved during 1998. Improvements in the DAWN drug vocabulary resulted in revisions to estimates for 1994 through 2000.¹¹ The charts, tables, and graphs in this publication present only revised estimates.

HOW TO USE THIS PUBLICATION

This issue of *ED Trends From DAWN* examines the nature of trends in drug-related ED episodes and focuses almost exclusively on the preliminary estimates for the first half of 2002 with statistical comparisons to the first half of 2001. Tables showing the 8 full years 1994 to 2001 have been discussed and published previously, but are reproduced here for ease of reference. In the full-year tables, statistical tests are used to compare full year 2001 estimates with those for 2000, 1999, and 1994. For half years, estimates for the latest half-year period are compared with those for the previous 2 half years. Each table displays the percent change for statistically significant differences. Actual *p*-values are still available in the companion tables of RSEs, which are published on the Internet.

The presentation of ED findings in this publication is divided into the following sections, which mirror the order of the tables in this publication:

- Trends in major substances of abuse, such as cocaine, heroin, and "club drugs;"
- Trends in other substances of abuse, such as prescription and over-the-counter (OTC) drugs;
- Trends for the 21 metropolitan areas oversampled in DAWN; and
- Discussion of results.

Population-based rates are discussed within these sections by topic, because the rates are best used to supplement the other estimates of episodes and mentions. By considering the estimates of drug mentions and episodes relative to the size of the population at risk, the rates yield standardized measures that can be compared across selected drugs, metropolitan areas, and gender and age groups.

¹¹ A thorough description of the revisions to the DAWN drug vocabulary and the impact of those revisions on published estimates can be found in Appendixes A and B of the *ED Trends From DAWN, Preliminary Estimates January–June 2001 with Revised Estimates 1994–2000*.

ORGANIZATION OF TABLES

In this section, we explain the organization of the tables in *ED Trends* and explain the classification of drugs in the context of these tables.

The table numbering scheme is described in a separate exhibit on the inside of the front cover of this publication. Table numbers in this publication are identical to those in the last issue of the *ED Trends From DAWN*.

The tables in this publication are designed to array information from the very general to the very specific. This design responds directly to requests we receive for information at these different levels of detail. Figure 2 illustrates the general to specific organization of the tables.

Major Drug Categories

At the most general level (the left half of Figure 2), estimates are reported for major drug categories. Table 2.2.0 illustrates the standard layout of substances by drug categories. This table and others like it are divided into 2 panels with:

- “Major substances of abuse” (e.g., cocaine, heroin, and “club drugs”) in the top panel, and
- “Other substances of abuse” in the lower panel.

Specific content for each of these panels is described later in this section.

National estimates are provided for the major drug categories in one table. The same estimates are provided in separate tables for each of the 21 metropolitan areas oversampled by DAWN. For example, Table 2.2.0 contains national estimates, and Tables 2.2.1 through 2.2.21 contain estimates for each of the 21 DAWN metropolitan areas.

The third term in the table number always indicates the geographic area:

- **.0** for national estimates, and
- **.1 - .21** for the 21 metropolitan areas, where **.1** is always Atlanta, **.2** is always Baltimore, and so forth. The complete list of the metropolitan areas and their corresponding numbers is provided on the inside of the front cover.

Component Drugs

At a more specific level (the right half of Figure 2), a second set of tables lists the component drugs classified under the 5 largest categories: major substances of abuse, psychotherapeutic agents, CNS agents, respiratory agents, and cardiovascular agents.

National estimates are provided for each of the component drugs; these are followed by estimates for component drugs for each of the 21 metropolitan areas.

This is more detailed drug information than is available from any other substance abuse data system. In response to requests, both high and low frequency terms are displayed, as follows:

- Table 2.4.0 (estimates) and 12.4.0 (rates): full-year estimates for component drugs of the major substances of abuse. Corresponding half-year estimates are published in Tables 2.3.0 and 12.3.0, respectively.

These tables include all the terms, including street names, reported to DAWN for the major substances of abuse. For example, users will consult this table to find estimates for “crack,” which is subsumed under the major substance “cocaine” in Tables 2.1.0 and 2.2.0, and to see the relative frequency of particular terms.

- Table 2.6.0 (and 12.6.0): full-year estimates for component drugs of psychotherapeutic agents. Corresponding half-year estimates are published in Tables 2.5.0 and 12.5.0, respectively.
- Table 2.8.0 (and 12.8.0): full-year estimates for component drugs of CNS agents. Corresponding half-year estimates are published in Tables 2.7.0 and 12.7.0, respectively.
- Table 2.10.0 (and 12.10.0): full-year estimates for component drugs of respiratory agents. Corresponding half-year estimates are published in Tables 2.9.0 and 12.9.0, respectively.
- Table 2.12.0 (and 12.12.0): full-year estimates for component drugs of cardiovascular agents. Corresponding half-year estimates are published in Tables 2.11.0 and 12.11.0, respectively.

Except for the major substances of abuse, component drugs are always expressed at the generic substance level (e.g., fluoxetine). No published estimates are provided by brand (trade) name. Tabulations of component drugs will include all substances in the category, regardless of the frequency with which they were reported to DAWN. For example, users interested in the trends in ED visits involving particular narcotic analgesics will consult Table 2.8.0.

Major Substances of Abuse

The major substances of abuse include the most common illicit drugs and drug categories reported to DAWN, alcohol reported in combination with any other substance reported to DAWN, and lower frequency drugs of particular policy interest (e.g., club drugs such as Ecstasy and GHB).

The 15 categories in the major substances of abuse are grouped in a panel at the top of summary tables (e.g., Table 2.2.0) for ease of reference. For each of the major substances, component drugs—that is, the specific terms, including street names as they were reported to DAWN—are enumerated in Table 2.4.0 (and Table 2.3.0 for half years). The 15 major substances of abuse are:

Alcohol-in-combination. This is the most frequent drug reported to DAWN, even though it is reported only when present in combination with another reportable drug.

Cocaine. This category includes both powder and crack cocaine. Estimates for these and other specific terms are available in the component drug tables.

Heroin. ED estimates for heroin and morphine are tabulated separately (with ED morphine estimates presented under narcotic analgesics, below).¹²

Marijuana. This category includes both marijuana and hashish.

Amphetamines. This class of substances has been extracted from the category of CNS stimulants because of its importance as a major substance of abuse. For purposes of classification, “amphetamines” (plural) includes a class of compounds derived from or related to the drug amphetamine. Although some “designer” drugs fall into the class of amphetamines, we choose to report some of them (e.g., methamphetamine) individually as major substances of abuse. This category does not include other CNS stimulants, such as caffeine or methylphenidate.

Methamphetamine. This category includes methamphetamine and the term “speed.”

MDMA (methylenedioxymethamphetamine, Ecstasy). This is the “designer” or “club” drug commonly known as Ecstasy. It is classified separately as a major substance of abuse because of widespread interest.

Ketamine. This is a veterinary anesthetic classified separately as a major substance of abuse because of widespread interest. It is another of the “designer” or “club” drugs.

LSD. LSD is listed separately from other hallucinogens because of widespread interest.

PCP. PCP is listed separately from other hallucinogens because of widespread interest.

Miscellaneous hallucinogens. This category includes hallucinogens other than LSD and PCP.

Flunitrazepam (Rohypnol). Flunitrazepam is a benzodiazepine that is not legal for marketing in the United States. It is reported under major substances because of increased interest in its use as a “designer” or “club” drug. It is excluded from the list of benzodiazepines described below.

Gamma hydroxy butyrate (GHB). This category includes GHB and its precursor gamma butyrolactone (GBL). It is another of the “designer” or “club” drugs.

Inhalants. Inhalants include anesthetic gases and certain nonpharmaceuticals for which the documented route of administration was inhalation.

To be classified as inhalants, anesthetic gases are extracted from the category CNS agents, general anesthetics. These substances have the physical property at room temperature

¹² In contrast, heroin and morphine are combined in tabulations of DAWN mortality data. It is often impossible to distinguish heroin from morphine during death investigations because the toxicology tests used to identify a drug involved in a drug-related death rely on a metabolite common to both drugs. This is the only such difference in drug classification between DAWN ED and mortality data.

of being a gas or are delivered as a gas and therefore are presumed to have been inhaled. The anesthetic gases include nitrous oxide, ether, and chloroform.

To be classified as an inhalant, a nonpharmaceutical substance must have a psychoactive effect when inhaled and falls into one of 3 subcategories: volatile solvents, nitrites, or chlorofluorohydrocarbons (see Appendix D).

Illicit combinations. This category includes compounds composed of 2 or more major substances of abuse that are mixed and taken together. For example, “speedball,” which usually refers to the combination of heroin and cocaine taken at once, would be classified as an illicit combination, whereas separate mentions of heroin and cocaine would be classified separately in the categories heroin and cocaine. Compounds consisting of a major substance of abuse and another substance are classified in the category of the major substance (e.g., heroin with scopolamine is classified as heroin).

Other Substances of Abuse

Other substances of abuse are summarized by pharmaceutical category (e.g., Table 2.2.0) using the categories and category assignments that are an integral part of the *Multum Lexicon* (the basis for DAWN’s drug vocabulary), with a few exceptions noted here. Many of these substances are marketed legally as prescription and OTC medications. Readers should note that the purpose for which these substances are intended may be quite different from the effect for which these substances are abused. Since it is impossible to know patients’ actual intentions when abusing a substance, we have chosen to classify these substances by their therapeutic uses. Some drugs may have more than one therapeutic use and could be assigned to multiple categories. To avoid duplication, each drug is assigned to a single therapeutic category and is tabulated only once.

Four of the categories under other substances of abuse are divided into finer subcategories, and the component drugs for these 4 categories are displayed in subsequent tables (e.g., Tables 2.6.0, 2.8.0, 2.10.0, and 2.12.0).

Psychotherapeutic agents are divided into the following categories:

- Antidepressants
 - MAO inhibitors
 - SSRI antidepressants
 - Tricyclic antidepressants
 - Miscellaneous antidepressants
- Antipsychotics
 - Phenothiazine antipsychotics
 - Psychotherapeutic combinations
 - Thioxanthenes
 - Miscellaneous antipsychotic agents
- Anxiolytics, sedatives, and hypnotics
 - Barbiturates
 - Benzodiazepines – This category excludes the benzodiazepine flunitrazepam (Rohypnol), which was assigned to major substances of abuse.
 - Miscellaneous anxiolytics, sedatives, and hypnotics

- CNS stimulants. This category excludes the CNS stimulants that were assigned to major substances of abuse: amphetamines, methamphetamine, and MDMA (Ecstasy).

Central nervous system (CNS) agents are divided into the following categories:

- Analgesics
 - Antimigraine agents
 - Cox-2 inhibitors
 - Narcotic analgesics and narcotic analgesic combinations – This category excludes heroin, which is classified as a major substance of abuse.
 - Nonsteroidal anti-inflammatory agents
 - Salicylates and salicylate combinations
 - Miscellaneous analgesics and miscellaneous analgesic combinations
 - Analgesic combinations NTA
- Anorexiant
- Anticonvulsants
- Antiemetic/antivertigo agents
- Antiparkinson agents
- General anesthetics – This category excludes the anesthetic gases that were assigned to major substances of abuse as inhalants.
- Muscle relaxants
- Miscellaneous CNS agents

Respiratory agents are divided into the following categories:

- Antihistamines
- Bronchodilators
- Decongestants
- Expectorants
- Upper respiratory combinations
- Respiratory agents not tabulated above (NTA) – This category captures respiratory agents that did not fit into the 5 other categories of respiratory agents.

Cardiovascular agents are divided into the following categories:

- Antiadrenergic agents, centrally acting
- Beta-adrenergic blocking agents
- Calcium channel blocking agents
- Diuretics
- Cardiovascular agents NTA – This category has been added to capture cardiovascular agents that did not fit into the 4 other categories of cardiovascular agents.

As noted earlier, the general categories used in Table 2.2.0 are expanded in Tables 2.4.0 through 2.12.0 to enumerate the component drugs for the 4 major categories: psychotherapeutic agents, CNS agents, respiratory agents, and cardiovascular agents and their associated subcategories. For example, Table 2.2.0 presents mentions of narcotic analgesics under CNS agents; mentions of particular narcotic analgesics—morphine, codeine, and others—are displayed in Table 2.8.0.

In the tables enumerating component drugs, only generic names are used. Brand (trade) names are not used because estimates for particular brands are considered to be unreliable.¹³ Therefore, for example, mentions of the miscellaneous analgesic acetaminophen are tabulated as “acetaminophen,” not Tylenol.

Users of DAWN estimates have told us that it is not useful to report only the most frequently occurring substances. Therefore, in Tables 2.4.0 through 2.12.0, substances are enumerated in their relevant category, regardless of the numbers of mentions estimated from DAWN.

The following 6 categories from the *Multum Lexicon* are presented without subdivisions due to the low number of mentions:

- Alternative medicines
- Anti-infectives
- Gastrointestinal agents
- Hormones
- Nutritional products
- Topical agents

Finally, 2 additional categories, “drug unknown” and “all other substances NTA” do not appear in the *Multum Lexicon* but are needed to complete the classification of substances for DAWN.

Drug unknown. This includes 2 types of cases: those in which the drug was reported to DAWN as “unknown” and those in which drugs were reported to DAWN as “polysubstances.” For the purposes of DAWN, polysubstance refers to the abuse of more than one substance when the individual substances were not identified by the source record. Because DAWN cases are identified through retrospective medical chart review, there will always be cases in which the drug abuse was known but the particular substance was unknown or unknowable. Since 1995, reporting of unknown substances seems to have stabilized at about 2 to 3 percent of drug mentions.

All other substances NTA. This category contains any substance reported to DAWN that could not be classified in the categories noted above and has too few mentions to warrant its own entry in DAWN tables. This category currently includes: antihyperlipidemic agents, antineoplastics, biologicals, coagulation modifiers, immunologic agents, miscellaneous agents, and plasma expanders. Miscellaneous agents include: antidotes, antigout agents, antipsoriatics, antirheumatics, chelating agents, cholinergic muscle stimulants, genitourinary tract agents, impotence agents, local injectable anesthetics, miscellaneous uncategorized agents, psoralens, radiocontrast agents, and viscosupplementation agents.

This category also includes certain legacy terms that could not be assigned reliably to any category. These include ambiguous, nonspecific terms that could fall into any of several categories (e.g., “AIDS medicine” could be an anti-infective, an anticonvulsant, or any number of other drugs); undocumented, nonspecific terms (e.g., “thought organizer”); and street terms for illicit substances that could not be linked reliably to a particular illicit substance (e.g., “T,” “butterflies”).

¹³ This issue has been discussed in greater detail in previous issues of *ED Trends From DAWN*.

We will monitor the content of this category to avoid its uncontrolled expansion in the future. Should a substance or class of substances begin to show significant growth, we intend to add such information to the published categories rather than allow this “all other” category to degrade over time. In addition, regular updates of the *Multum Lexicon* will introduce new prescription and OTC substances as they are approved for marketing and before they begin to appear in DAWN.

ADDITIONAL CONTENT AVAILABLE ON THE INTERNET

Although this publication includes a large number of tables, even more detail is available through tables that are published only on the Internet. These additional tables can be accessed online at <http://www.samhsa.gov/oas/dawn.htm> and <http://www.DAWNinfo.net>. Tables published exclusively on the Internet are:

- Additional tables of estimates by metropolitan area. For ease of reference, these are listed in the table of contents of *ED Trends* and their location noted.
- Relative standard errors (RSEs) for estimates provided in this publication, in a corresponding tabular format. The RSEs used for population-based rates are the same as those used for other DAWN estimates. Although there may be slight differences in the RSEs calculated for the DAWN estimates and the RSEs that would be appropriate for the population-based rates (due to sampling error in the current population estimates), they are sufficiently close for the purpose of this publication.
- Updated indexes listing generic and brand names for prescription and OTC substances. No published estimates are provided by brand (trade) name. The index is provided as an aid for readers who may be unfamiliar with the generic names used in this publication. The updated index is not printed in each issue of *ED Trends* due to size.¹⁴

¹⁴ An earlier version of this index was printed as Appendix I in *Emergency Department Trends From the Drug Abuse Warning Network Preliminary Estimates January–June 2001 with Revised Estimates 1994–2000*. The index is updated periodically.

Figure 1
Relative standard errors (RSEs) for drug-related episodes by metropolitan area:
January–June 2002





Figure 2
Tables in ED Trends From DAWN



TRENDS IN ED DRUG EPISODES AND MAJOR SUBSTANCES OF ABUSE

This section presents semi-annual estimates from DAWN for total drug-related ED episodes and mentions of major substances of abuse.

“Major substances of abuse” include the most common illicit drugs reported to DAWN, alcohol reported in combination with any other substance reported to DAWN, and lower frequency drugs of particular policy interest (e.g., club drugs such as Ecstasy and GHB). The specific terms (including street names) reported to DAWN for each drug category are listed, with corresponding mentions from July–December 1997 through January–June 2002, in Table 2.3.0 and Table 12.3.0 (corresponding rates per 100,000 population). Corresponding full-year tables for 1994 through 2001 (Tables 2.4.0 and 12.4.0) are also available.

One ED episode can include mentions of one drug alone or mentions of multiple drugs. Therefore, the number of drug mentions exceeds the number of episodes. Major substances of abuse, such as cocaine, heroin, and marijuana, are often reported in combination with other drugs. Alcohol-in-combination is reportable to DAWN only when present in combination with another reportable drug.

The following discussion focuses primarily on comparisons of preliminary estimates for the first half of 2002 versus the first half of 2001. The potential for seasonal variations makes comparisons of the second half of 2001 with the first half of 2002 less reliable.

DAWN estimates for 2001 are based on data from a nationally representative sample of 458 hospitals (Table 1.1).

TOTAL DRUG-RELATED ED EPISODES

- From January through June 2002, DAWN estimates that there were 308,558 drug abuse-related ED episodes in the coterminous U.S. with 564,196 drug mentions (on average, 1.8 drugs per episode) (Table 2.1.0).
- There was no statistically significant difference between the first half of 2001 and the first half of 2002 in total drug-related ED episodes or ED drug mentions (Table 2.1.0). Total ED visits (that is, ED visits for any reason) increased 0.1 percent during this period.
- In the first half of 2002, drug abuse-related ED visits occurred at the rate of 121 ED episodes per 100,000 population in the coterminous U.S. (Table 12.1.0).
- From the first half of 2001 to the first half of 2002, none of the 21 metropolitan areas oversampled in DAWN had increases in drug abuse episodes, but there were significant decreases in drug episodes in 4 metropolitan areas (Table 3.1):
 - Seattle (-54%, from 5,720 to 2,656 episodes),
 - Dallas (-22%, from 3,369 to 2,638),

- Chicago (-16%, from 16,526 to 13,937), and
- San Diego (-12%, from 3,615 to 3,194).

MAJOR SUBSTANCES OF ABUSE

- From the first half of 2001 to the first half of 2002, the only major substance of abuse that changed significantly was LSD, with mentions decreasing 78 percent (from 1,882 mentions in the first half of 2001 to 407 mentions in the first half of 2002) (Table 2.1.0).

ALCOHOL-IN-COMBINATION

- Alcohol-in-combination was mentioned in 32 percent of ED drug episodes in the first half of 2002 (97,527 mentions) and remains the most common substance reported in drug-related ED visits (Table 2.1.0 and Figure 3). Alcohol is reported to DAWN only when present in combination with another reportable drug, so the actual number of alcohol-related ED visits is higher than the DAWN estimate for alcohol-in-combination.
- Mentions of alcohol-in-combination were statistically unchanged from the first half of 2001 to the first half of 2002 (Table 2.1.0 and Figure 3).
- From the first half of 2001 to the first half of 2002, only Buffalo had a significant increase in mentions of alcohol-in-combination (56%, from 804 to 1,252) (Table 3.5). Significant decreases in mentions of alcohol-in-combination were found in 4 metropolitan areas oversampled in DAWN:
 - Seattle (-46%, from 1,469 to 800 mentions),
 - San Francisco (-29%, from 1,010 to 717),
 - Dallas (-28%, from 934 to 670), and
 - Phoenix (-23%, from 1,296 to 1,004).

COCAINE, HEROIN, MARIJUANA

- Cocaine continues to be the most frequently mentioned illicit substance, present in 30 percent of ED episodes (91,687 mentions) in the first half of 2002. Cocaine was followed in frequency by marijuana (18%, 55,727 mentions) and heroin (14%, 42,571 mentions) (Table 2.1.0 and Figure 3).
- Mentions of cocaine, heroin, and marijuana remained statistically stable from the first half of 2001 to the first half of 2002. (Table 2.1.0).
- Almost a quarter of the cocaine mentions in the first half of 2002 (23%, 20,694 mentions) were attributed specifically to “crack” (Table 2.3.0). Most cocaine mentions (76%, 70,106) were reported to DAWN simply as “cocaine,” and it is not possible to determine what proportion of these might be crack.

- From the first half of 2001 to the first half of 2002, significant increases in cocaine mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.7):
 - Minneapolis (47%, from 462 to 681 mentions) and
 - Denver (47%, from 631 to 926).
- From the first half of 2001 to the first half of 2002, significant decreases in cocaine mentions were found in 7 metropolitan areas (Table 3.7):
 - Seattle (-67%, from 1,660 to 551 mentions),
 - Dallas (-32%, from 964 to 654),
 - Detroit (-32%, from 4,160 to 2,820),
 - Washington, DC (-28%, from 1,440 to 1,032),
 - San Francisco (-21%, from 1,220 to 964),
 - Chicago (-20%, from 8,269 to 6,614), and
 - San Diego (-11%, from 439 to 389).
- From the first half of 2001 to the first half of 2002, significant increases in heroin mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.9):
 - Buffalo (71%, from 283 to 484 mentions), and
 - Denver (37%, from 380 to 519).
- From the first half of 2001 to the first half of 2002, significant decreases in heroin mentions were found in 7 metropolitan areas (Table 3.9):
 - Seattle (-47%, from 903 to 475 mentions),
 - Washington, DC (-42%, from 1,024 to 591),
 - Dallas (-41%, from 251 to 147),
 - Detroit (-32%, from 2,102 to 1,440),
 - Baltimore (-24%, from 2,593 to 1,977),
 - San Diego (-21%, from 401 to 316), and
 - Phoenix (-20%, from 372 to 298).

- From the first half of 2001 to the first half of 2002, significant increases in marijuana mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.11):
 - Miami (30%, from 920 to 1,195 mentions) and
 - San Diego (20%, from 521 to 625).
- From the first half of 2001 to the first half of 2002, significant decreases in marijuana mentions were found in 4 metropolitan areas oversampled in DAWN (Table 3.11):
 - Seattle (-65%, from 858 to 298),
 - Buffalo (-49%, from 374 to 192),
 - San Francisco (-44%, from 387 to 217), and
 - Dallas (-36%, from 570 to 364).

AMPHETAMINES AND METHAMPHETAMINE

- In the first half of 2002, amphetamines were mentioned in 3 percent of DAWN ED episodes (10,079 mentions, or 4 mentions per 100,000 population) (Tables 2.1.0 and 12.1.0). From the first half of 2001 to the first half of 2002, no significant change was evident.
- There were 6,136 methamphetamine mentions (2 per 100,000 population) in the first half of 2002 (Tables 2.1.0 and 12.1.0). These estimates were not statistically changed from the first half of 2001.
- Most mentions of amphetamines are attributed simply to “amphetamine,” while most mentions of methamphetamine are attributed simply to “methamphetamine” or “speed” (Tables 2.3.0 and 2.4.0). It is impossible to know the accuracy of distinctions between amphetamine and methamphetamine. Together they accounted for 16,215 mentions in the first half of 2002.
- From to the first half of 2001 to the first half of 2002 (Tables 3.13 and 3.15):
 - Significant increases in mentions of amphetamines were found in 2 metropolitan areas: Denver (57%, from 163 to 256 mentions) and San Diego (31%, from 432 to 566).
 - Mentions of amphetamines decreased in 4 metropolitan areas: Seattle (-70%, from 345 to 104), Philadelphia (-45%, from 228 to 126), San Francisco (-26%, from 376 to 279), and Dallas (-24%, from 187 to 143).
 - Of the metropolitan areas with at least 100 mentions of methamphetamine, there were significant decreases in 2 metropolitan areas: Seattle (-31%, from 166 to 115) and San Diego (-25%, from 344 to 257). There were no significant increases.

CLUB DRUGS

- No significant changes from the first half of 2001 to the first half of 2002 were evident for the club drugs MDMA (Ecstasy) (2,303 mentions in the first half of 2002), GHB (2,024), or Ketamine (152) (Table 2.1.0).
- None of the 21 metropolitan areas oversampled in DAWN had more than 100 mentions of the club drugs in the first half of 2002 (Tables 3.17, 3.19, 3.27, and 3.29).

OTHER TRENDS

- For the coterminous U.S., LSD mentions decreased 78 percent (from 1,882 to 407) from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- For the coterminous U.S., no significant changes from the first half of 2001 to the first half of 2002 were evident for (Table 2.1.0):
 - PCP (3,257 mentions in the first half of 2002),
 - Miscellaneous hallucinogens (620),
 - Inhalants (559), or
 - Illicit combinations (118).

DEMOGRAPHIC CHARACTERISTICS OF PATIENTS

- Total drug-related ED episodes were unchanged across demographic subgroups from the first half of 2001 to the first half of 2002 (Table 4.1.0). Similarly, mentions of alcohol-in-combination, cocaine, marijuana, amphetamines, methamphetamine, MDMA (Ecstasy), Ketamine, PCP, and GHB were stable across demographic subgroups (Tables 4.1.0 through 4.33.0).
- Comparing the first halves of 2001 and 2002:
 - Mentions of heroin declined 18 percent (from 14,924 to 12,260) among patients who were black (Table 4.9.0).
 - Mentions of LSD declined across most demographic subgroups: both genders, white and black patients, as well as patients age 20 and over (Table 4.21.0).

EPISODE CHARACTERISTICS

- Characteristics of drug-related ED episodes overall were unchanged from the first half of 2001 to the first half of 2002 (Table 5.1.0).
 - More than half (55%) of drug-related ED episodes involved multiple drugs during the first half of 2002.
 - The motive for drug use was cited as dependence in more than one-third (37%), suicide in another 29 percent, and psychic effects in 20 percent of episodes during the first half of 2002. Motive was unrecorded in 13 percent of cases.
 - The reason for the ED visit was overdose in 40 percent, unexpected reaction in 18 percent, and seeking detoxification in 17 percent. Reason for contact was unrecorded in 5 percent of cases.
 - Patients were admitted to the hospital (49%) and treated and released (48%) in nearly equal proportions.

Figure 3
ED drug-related episodes and alcohol-in-combination, cocaine, heroin, and marijuana mentions: July–December 1997 through January–June 2002





Figure 4
Relative standard errors (RSEs) for major substances of abuse: January–June 2002



TRENDS IN OTHER SUBSTANCES OF ABUSE

DAWN also receives reports of ED episodes involving the nonmedical use of legal drugs. These can involve deliberate abuse of prescribed or legally obtained over-the-counter (OTC) medications or of pharmaceuticals diverted for abuse. Accidental overdoses or adverse reactions to OTC or prescription drugs taken as directed are not reportable to DAWN unless the drugs were present in combination with an illicit drug.

These “other substances of abuse” are tabulated first by categories composed of similar substances (Tables 2.1.0 and 12.1.0 for half year estimates and rates, respectively) and then by generic drug name for the component drugs in each of the largest categories: psychotherapeutic agents (Tables 2.5.0 and 12.5.0), CNS agents (Table 2.7.0 and 12.7.0), respiratory agents (Tables 2.9.0 and 12.9.0), and cardiovascular agents (Tables 2.11.0 and 12.11.0). Corresponding full year tables (Tables 2.6.0, 2.8.0, 2.10.0, and 2.12.0 for estimates and Tables 12.6.0, 12.8.0, 12.10.0, and 12.12.0 for rates) are also available.

By design, all drug mentions in DAWN are tabulated as either major substances of abuse or other substances of abuse. There is no double counting, and the deliberate assignment of drugs into major substances is the result of specific interest in such substances.

Only generic drug names are presented in DAWN publications. DAWN estimates should not be attributed to drugs marketed under particular brand (trade) names. DAWN data are extracted from medical records produced in the course of health care delivery (no patient is ever interviewed), so DAWN case reports contain information about particular substances as that information was documented in the ED medical record. Any prescription or OTC drug may be reported to DAWN by its brand (trade) name, generic name, or chemical name, depending on what was documented in the source record. There is no way to discern whether the brand names in the medical record are always accurate or how frequently brands might have been recorded in generic terms. Therefore, we do not publish estimates for particular brands because we consider them to be unreliable. An index linking brand to generic names is available online at <http://www.samhsa.gov/oas/dawn.htm> and <http://www.DAWNinfo.net>. The index is provided solely as an aid to readers who may be unfamiliar with generic names.

In addition, many drug mentions are reported to DAWN by drug type without the drug being named specifically. For publication, these are referred to by the drug type-NOS (not otherwise specified). For example, reports of “benzodiazepine” or “benzos” that do not name a specific benzodiazepine are tabulated as “benzodiazepines-NOS.”

This discussion focuses mainly on comparisons of estimates from the first half of 2001 to the first half of 2002.

OTHER SUBSTANCES OF ABUSE

- DAWN estimates that other substances of abuse (251,015 mentions) comprised 44 percent of total ED drug mentions in the first half of 2002 (Table 2.1.0). Although the vast majority of these other substances are marketed legally by prescription or OTC, it is impossible to know from DAWN the number of ED visits related to the abuse of prescription drugs by patients with legitimate prescriptions.
- ED mentions of other substances of abuse in the first half of 2002 were most concentrated in 2 categories—psychotherapeutic agents (104,687 mentions) and central nervous system (CNS) agents (108,081)—in nearly equal proportions (19% of total ED mentions each) (Table 2.1.0). From the first half of 2001 to the first half of 2002:
 - Mentions of psychotherapeutic agents overall were stable, as were mentions for the subcategories of psychotherapeutic agents (antidepressants; antipsychotics; anxiolytics, sedatives, and hypnotics; and CNS stimulants).
 - Mentions of CNS agents overall were stable. However, among the subcategories of CNS agents, mentions of narcotic analgesics/combinations increased 16 percent (from 47,683 to 55,311 mentions), mentions of miscellaneous analgesics/combinations decreased 17 percent (from 21,447 to 17,849), and mentions of anorexiant increased 171 percent (from 383 to 1,038).


Narcotic Analgesics

- When considered together, narcotic analgesics/combinations comprised 55,311 mentions or 10 percent of ED mentions estimated for the coterminous U.S. in the first half of 2002 (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, mentions of narcotic analgesics/combinations rose 16 percent (Table 2.1.0 and Figure 5).
- Among the most frequently mentioned narcotic analgesics/combinations (Table 2.7.0):
 - Estimates for codeine/combinations (2,317 mentions in the first half of 2002), hydrocodone/combinations (12,033 mentions), morphine/combinations (1,122 mentions), and propoxyphene/combinations (2,486 mentions) were stable from the first half of 2001 to the first half of 2002, as were mentions of unnamed narcotic analgesics (NOS, 18,970 mentions) and of methadone (5,190 mentions).
 - ED mentions for the category of oxycodone/combinations were not statistically changed from the first half of 2001 to the first half of 2002. However, mentions of oxycodone specifically rose significantly from the first half of 2001 to the first half of 2002 (a 59% increase, from 4,940 to 7,828 mentions).

Other Substances

- Respiratory agents comprised 1 percent (6,596) of total ED drug mentions in the first half of 2002 (Table 2.1.0). Mentions of respiratory agents overall and its major subcategories were unchanged from the first half of 2001 to the first half of 2002.
- Cardiovascular agents comprised 1 percent (6,569) of total ED drug mentions in the first half of 2002 (Table 2.1.0). Mentions of cardiovascular agents rose 53 percent (from 4,285) from the first half of 2001 to the first half of 2002.
- None of the smaller categories of other substances experienced a significant change from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- The particular drugs involved in ED visits are sometimes unknown or unknowable. In the first half of 2002, there were 15,311 such mentions (3% of total mentions) (Table 2.1.0).

Figure 5
ED mentions of selected narcotic analgesics:
July–December 1997 through January–June 2002



SELECTED TRENDS IN 21 METROPOLITAN AREAS

This section presents findings for the 21 metropolitan areas oversampled in DAWN, with particular attention to the major substances of abuse. As noted previously, “major substances of abuse” include the most common illicit drugs reported to DAWN, alcohol present in combination with any other substance reported to DAWN, and lower frequency drugs of particular policy interest (e.g., club drugs such as Ecstasy and GHB).

This section of *ED Trends* focuses primarily on Tables 3.1 to 3.33 (ED episodes and mentions) and 13.1 to 13.33 (rates of ED episodes and mentions per 100,000 population). These tables summarize for all the 21 metropolitan areas the estimates for: total episodes, total mentions, and the 15 major substances of abuse. Those interested in making comparisons across metropolitan areas should rely on the rates per 100,000 population because these account for differences in population across the metropolitan areas.

These are the same estimates presented separately for each metropolitan area in Tables 2.2.1 to 2.2.21 (episodes and mentions) and 12.2.1 to 12.2.21 (rates).¹⁵ As noted in the introduction, 3-part table numbers ending in “.1” to “.21” contain estimates for the 21 metropolitan areas. Some readers will be interested in findings only for a particular area. For these readers, we also provide 21 complete sets of tables, one for each metropolitan area, online at <http://www.samhsa.gov/oas/dawn.htm> and <http://www.DAWNinfo.net>.

Readers should note that very small changes in the estimates for some metropolitan areas may result in statistically significant differences. This occurs when all or nearly all eligible hospitals are included in the sample for those cities.

TOTAL DRUG-RELATED EPISODES

- Nationwide, total ED drug episodes remained statistically unchanged from the first half of 2001 to the first half of 2002 (Table 3.1). However, from the first half of 2001 to the first half of 2002, significant decreases in drug episodes were found in 4 metropolitan areas oversampled in DAWN:
 - Seattle (-54%, from 5,720 to 2,656 episodes),
 - Dallas (-22%, from 3,369 to 2,638),
 - Chicago (-16%, from 16,526 to 13,937), and
 - San Diego (-12%, from 3,615 to 3,194).

¹⁵ In addition, demographic characteristics of patients are presented in Tables 4.2.1 to 4.2.21 (episodes and mentions) and 14.2.1 to 14.2.21 (rates). Estimates of episode characteristics are presented in Tables 5.2.1 to 5.2.21 (there are no rates calculated for episode characteristics). Because of the detail involved, this publication focuses little on these estimates by metropolitan area.

ALCOHOL-IN-COMBINATION

- Mentions of alcohol-in-combination were stable for the coterminous U.S. from the first half of 2001 to the first half of 2002 (Table 3.5). In the metropolitan areas oversampled in DAWN, only Buffalo had a significant increase in mentions of alcohol-in-combination (56%, from 804 to 1,252 mentions) and 4 other metropolitan areas had significant decreases: Seattle (-46%, from 1,469 to 800), San Francisco (-29%, from 1,010 to 717), Dallas (-28%, from 934 to 670), and Phoenix (-23%, from 1,296 to 1,004).

COCAINE

- Nationwide, cocaine mentions remained statistically stable from the first half of 2001 to the first half of 2002 (Table 3.7). Significant increases in cocaine mentions were found in 2 metropolitan areas oversampled in DAWN: Minneapolis (47%, from 462 to 681 mentions) and Denver (47%, from 631 to 926). Significant decreases were found in 7 metropolitan areas: Seattle (-67%, from 1,660 to 551), Dallas (-32%, from 964 to 654), Detroit (-32%, from 4,160 to 2,820), Washington, DC (-28%, from 1,440 to 1,032), San Francisco (-21%, from 1,220 to 964), Chicago (-20%, from 8,269 to 6,614), and San Diego (-11%, from 439 to 389).

HEROIN

- Nationwide, ED mentions of heroin remained stable in the coterminous U.S. from the first half of 2001 to the first half of 2002 (Table 3.9). From the first half of 2001 to the first half of 2002, significant increases in heroin mentions were found in 2 metropolitan areas oversampled in DAWN (Table 3.9): Buffalo (71%, from 283 to 484 mentions) and Denver (37%, from 380 to 519). Significant decreases were found in 7 metropolitan areas: Seattle (-47%, from 903 to 475 mentions), Washington, DC (-42%, from 1,024 to 591), Dallas (-41%, from 251 to 147), Detroit (-32%, from 2,102 to 1,440), Baltimore (-24%, from 2,593 to 1,977), San Diego (-21%, from 401 to 316), and Phoenix (-20%, from 372 to 298).

MARIJUANA

- Nationwide, mentions of marijuana remained statistically stable from the first half of 2001 to the first half of 2002 (Table 3.11). Significant increases in marijuana mentions were found in 2 metropolitan areas oversampled in DAWN: Miami (30%, from 920 to 1,195 mentions) and San Diego (20%, from 521 to 625). Significant decreases were found in 4 metropolitan areas: Seattle (-65%, from 858 to 298), Buffalo (-49%, from 374 to 192), San Francisco (-44%, from 387 to 217), and Dallas (-36%, from 570 to 364).

AMPHETAMINES AND METHAMPHETAMINE

- Nationwide, mentions of amphetamines and methamphetamine remained stable from the first half of 2001 to the first half of 2002 (Tables 3.13 and 3.15).
- From the first half of 2001 to the first half of 2002:
 - Increases in mentions of amphetamines were found in 2 metropolitan areas (Table 3.13): Denver (57%, from 163 to 256 mentions) and San Diego (31%, from 432 to 566).
 - Decreases in mentions of amphetamines were found in 4 metropolitan areas (Table 3.13): Seattle (-70%, from 345 to 104), Philadelphia (-45%, from 228 to 126), San Francisco (-26%, from 376 to 279), and Dallas (-24%, from 187 to 143).
 - There were no significant increases in mentions of methamphetamine in any of the metropolitan areas with at least 100 mentions (Table 3.15), but decreases were found in 2: Seattle (-31%, from 166 to 115) and San Diego (-25%, from 344 to 257).

CLUB DRUGS

- None of the metropolitan areas oversampled in DAWN had more than 100 mentions of the club drugs in the first half of 2002 (Tables 3.17, 3.19, 3.27, and 3.29).

NARCOTIC ANALGESICS AND NARCOTIC ANALGESIC COMBINATIONS

- Nationwide, ED mentions of narcotic analgesics/combinations rose 16 percent (from 47,683) from the first half of 2001 to the first half of 2002 (Table 2.1.0).
- From the first half of 2001 to the first half of 2002, significant increases in mentions of narcotic analgesics/combinations were found in 2 of the 21 metropolitan areas oversampled in DAWN (Tables 2.1.1 through 2.1.21):
 - Baltimore (69%, from 1,140 to 1,929 mentions) and
 - Buffalo (42%, from 406 to 577).
- From the first half of 2001 to the first half of 2002, significant decreases in mentions of narcotic analgesics/combinations were found in 2 of the 21 DAWN metropolitan areas (Tables 2.1.1 through 2.1.21):
 - Seattle (-44%, from 1,179 to 655 mentions) and
 - San Francisco (-25%, from 403 to 304).

DISCUSSION OF RESULTS

This publication presents preliminary estimates from the DAWN emergency department (ED) component for the period from January to June 2002. Final estimates for the full years 1994 through 2001, which have been published previously, are also provided here for reference.

By definition, preliminary estimates are not final, and any conclusions from them are subject to change when the year's data submissions become complete and final estimates are produced. In addition to incomplete data, half-year preliminary estimates may reflect seasonal and other anomalies that will not persist in final estimates. Therefore, this discussion is relatively short, and we urge readers to consider the preliminary nature of the estimates in interpreting their meaning and the relationship to trends reported previously.

OVERVIEW OF FINDINGS

DAWN preliminary estimates presented for the first time in this publication show that total drug-related ED episodes and drug mentions were stable from the first half of 2001 to the first half of 2002. ED mentions of most of the major substances of abuse were unchanged from the first half of 2001 to the first half of 2002. LSD—with a 78 percent decrease in ED mentions—was the only major substance of abuse with a significant change at the national level from the first half of 2001 to the first half of 2002. Similarly, there were few changes in drug abuse episodes for any of the demographic subgroups. Mentions of heroin declined among patients who were black, and the decline in LSD mentions was evident across age, race, and age subgroups.

These preliminary estimates show no increases in total drug abuse episodes in the 21 metropolitan areas oversampled in DAWN from the first half of 2001 to the first half of 2002. However, decreases were evident in Seattle, Dallas, Chicago, and San Diego.

A similar pattern—increases in few metropolitan areas, decreases in more—was evident for most of the major substances of abuse. Only 1 metropolitan area (Buffalo) had an increase in mentions of alcohol-in-combination from the first half of 2001 to the first half of 2002, but decreases were evident in 4 (Seattle, San Francisco, Dallas, and Phoenix). Mentions of cocaine increased in 2 metropolitan areas (Minneapolis and Denver) but decreased in 7 (Seattle, Dallas, Detroit, Washington, DC, San Francisco, Chicago, and San Diego). Heroin mentions increased in 2 metropolitan areas (Buffalo and Denver) and decreased in 7 (Seattle, Washington, DC, Dallas, Detroit, Baltimore, San Diego, and Phoenix). Marijuana mentions increased in 2 metropolitan areas (Miami and San Diego) and decreased in 4 (Seattle, Buffalo, San Francisco, and Dallas). Mentions of amphetamines increased in 2 metropolitan areas (Denver and San Diego) and decreased in 4 (Seattle, Philadelphia, San Francisco, and Dallas). Mentions of methamphetamine declined in Seattle and San Diego.

Among the frequently mentioned prescription and over-the-counter medications, ED mentions of narcotic analgesics/combinations increased 16 percent from the first half of 2001 to the first half of 2002. Among the narcotic analgesics, the increase in mentions of oxycodone products (a subset of the category oxycodone/combinations) stood out, while mentions of most of the narcotic analgesics—the unnamed narcotic analgesics and methadone, as well as

products containing codeine, hydrocodone, morphine, and propoxyphene—were statistically unchanged.

LIMITATIONS

It is important to recognize that findings from DAWN alone cannot define an emerging drug abuse problem or quantify precisely the abuse potential of prescription drug products. Instead, DAWN identifies sentinel events—indicators of a potential drug abuse problem—which DAWN can then monitor over time. This information can be put together with information from other sources (other indicators) to determine whether a new drug abuse problem is emerging. Relying on information from DAWN alone would likely result in false positives—identification of problem substances when no problem exists—but this is a hazard when trying to track any problem in its early stages and it is not a hazard particular to DAWN.

DAWN stands virtually alone in publishing preliminary estimates for a portion of a year. We do so because of the intense interest in monitoring on-going trends, especially for illicit drugs, but we caution readers that preliminary estimates may yield premature conclusions. We urge caution especially in consideration of estimates that are small and/or unstable on an annual basis, because these estimates are even smaller and often more unstable when examined for a 6-month period. Because of the potential for seasonal distortions, we focus our attention primarily on comparisons of preliminary estimates for January–June 2002 with estimates for the same period in 2001. Finally, we emphasize that there is no guarantee that the statistically significant differences or the non-significant ones will hold up once data for 2002 are complete.

DAWN data show only one dimension of the total consequences of drug abuse, specifically the impact of drug use that manifests in visits to hospital EDs. DAWN does not measure the prevalence of drug use in the population, the untreated health consequences of drug use, or the impact of drug use on health care settings other than hospital EDs. For measures of prevalence, we refer readers to the National Household Survey on Drug Abuse (NHSDA), a national survey of households that explores drug abuse in the population.

Many factors can influence the estimates of ED visits, including trends in ED usage in general. Comparing the first half of 2002 to the first half of 2001, the number of drug-related ED visits was unchanged while ED visits for any reason increased a modest but statistically significant 0.1 percent. Drug users may visit EDs for a variety of reasons, only some of which may be life threatening. Some seek care in EDs for entry into detoxification and substance abuse treatment. These reasons almost certainly vary across the different substances reported to DAWN. Otherwise, changes in the number of drug-related emergencies may be due to changes in the use of particular drugs in combination; varying patterns of drug use, such as alterations in routes of administration; the amount of drug administered, its purity or price. Finally, estimates of drug-related ED episodes may increase or decrease over time for reasons unrelated to the size of the drug using population. Changes in access to certain health care settings or other factors may also influence findings from DAWN that focus only on ED visits.

APPENDIX A: RACE AND ETHNICITY DATA IN DAWN

Beginning in January 2000, the race and ethnicity categories on DAWN data collection forms changed to match a revised standard protocol.¹⁶ The new protocol permits separate reporting of race and Hispanic ethnicity, and it incorporates the ability to capture more than one race for an individual, a few modifications in nomenclature (e.g., “Black” was changed to “Black or African American”); division of certain categories (“Asian or Pacific Islander” was split into 2 categories, “Asian” and “Native Hawaiian or Other Pacific Islander”); and elimination of the “Other” category. The complete DAWN report form is reproduced in Appendix F.

Despite the increased detail allowed by the new categories, the actual race and ethnicity data extracted from source records and submitted to DAWN changed very little. This is because the source documents—ED medical records from which DAWN data are abstracted—rarely contain such detailed information on race and ethnicity of patients.

For reference, estimates of race and ethnicity in drug-related ED visits are presented in Table 1.10.¹⁷ This analysis, which is based on the most detailed coding of race and ethnicity in DAWN case reports, reveals that estimates for the following categories are too small to be meaningful:

- Two or more races (that is, 2 or more races were documented in the source record for the same individual),
- Hispanic or Latino ethnicity with any specific race indicated,
- American Indian or Alaska Native,
- Asian, and
- Native Hawaiian or Other Pacific Islander.

Therefore, in the tables of estimates in this and other DAWN publications we have retained the categories used previously to tabulate DAWN data, with one exception. A new category called “Race/ethnicity not tabulated above (NTA)” is used to tabulate those categories that are too small to report independently.¹⁸ All cases reported to DAWN as Hispanic or Latino ethnicity are tabulated as Hispanic race/ethnicity, regardless of race.

This lack of detailed race and ethnicity data in DAWN case reports also prevents us from generating rates per 100,000 population for race and ethnicity categories. Data from the 2000 decennial Census were collected and are being tabulated according to the revised race and ethnicity protocol and are therefore incompatible with DAWN estimates.

¹⁶ See Office of Management and Budget, *Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity*, *Federal Register*, 62 FR 58782, October 30, 1997.

¹⁷ These detailed estimates conform to the OMB guidance on tabulation of race and ethnicity data in Office of Management and Budget, *Draft Provisional Guidance on the Implementation of the 1997 Standards for the Collection of Federal Data on Race and Ethnicity*, February 17, 1999.

¹⁸ One exception is that if 2 races are reported and the second is reported as unknown, the episode is coded for the known race.

APPENDIX B: DETAILED DESCRIPTION OF DAWN

This section gives a detailed description of the methods and some of the history behind DAWN analysis. The section begins with a description of the sample design, followed by weighting, precision of the estimates, preliminary versus final estimates, rates per 100,000 population, and revision of the estimation system.

SAMPLE DESIGN

The Drug Abuse Warning Network (DAWN) is a voluntary, national data collection system that gathers information on substance abuse that manifests in visits to hospital emergency departments (EDs) in the coterminous U.S. Currently, DAWN provides semi-annual and annual estimates of the number of drug-related visits to hospital EDs from a nationally representative sample of hospitals located throughout the coterminous U.S. The DAWN system is managed by the Office of Applied Studies (OAS), a component of the Substance Abuse and Mental Health Services Administration (SAMHSA) of the U.S. Department of Health and Human Services (DHHS).

Several changes have been made to the sample design since DAWN began in 1972 under the Drug Enforcement Administration (DEA). In the early 1970s, the DAWN sample consisted of a random sample of hospital EDs. Over time, however, a number of facilities were lost from the original sample because of closures, mergers, attrition, or voluntary termination. New hospitals were recruited to participate, but no sample maintenance plan was devised for selecting new hospitals to sustain the randomness of the sample. As a result, attrition and nonrandom replacement led to a sample that was no longer representative of all hospital EDs in the coterminous U.S.

When the National Institute on Drug Abuse (NIDA) assumed responsibility for DAWN in 1980, one of the agency's goals was to implement a new sample that could be used to produce estimates for the Nation as a whole and for the separate DAWN metropolitan areas. Once a design was determined and the units were selected, the sample required the recruitment of 300 new hospitals. The cost of the project delayed its initiation until early 1986.

Hospitals eligible for DAWN are non-Federal, short-stay general surgical and medical hospitals in the coterminous U.S. that have a 24-hour ED. The American Hospital Association's (AHA) 1984 and 1985 Annual Surveys of Hospitals were used to obtain a sampling frame. (For a definition of sampling frame and other technical terms used in this publication, see the Glossary of Terms in Appendix D.)

Hospitals in the sampling frame were stratified according to several characteristics. First, the sampling frame was divided into the 21 DAWN metropolitan areas and the remainder of the country (called the National Panel). Hospitals having 80,000 or more annual ED visits were assigned to a single stratum for selection with certainty. Then, the remaining hospitals in the 21 metropolitan areas were classified by location (inside or outside the central city) and by whether the hospital had an organized outpatient department and/or a chemical/alcohol inpatient unit

(that is, whether it had zero, one, or both types of units). Similarly, hospitals in the National Panel were classified by the presence/absence of such units.

The 21 metropolitan area boundaries correspond to the Office of Management and Budget (OMB) 1983 definitions of Metropolitan Statistical Areas (MSAs) and Primary Metropolitan Statistical Areas (PMSAs) with a few exceptions. In the case of the Boston metropolitan area, the OMB definition was replaced by the definition for the New England County Metropolitan Area (NECMA). In several metropolitan areas, use of the PMSAs excluded some counties covered by DAWN prior to 1988, such as Nassau and Suffolk Counties in New York, certain counties in the Chicago area, and Niagara County in the Buffalo area. In other areas, such as Atlanta, counties not previously covered in DAWN were included. In addition to geographic coverage, the central cities in the new statistical areas differ from those in the old MSAs used previously in DAWN. For example, Hialeah joined Miami as a central city in the new Miami-Hialeah area, and Long Beach joined the Los Angeles-Long Beach area. In some instances in this publication, only the first city name is cited, but it always refers to the complete metropolitan area.

Sample sizes for the metropolitan areas and the National Panel were determined for each stratum so as to achieve specified levels of precision in the estimates. In this context, precision refers to the amount of sampling fluctuation inherent in the estimate; the less the fluctuation, the greater the precision. Target precision levels were expressed as relative standard errors (RSEs), defined as the ratio of the standard error (SE) of an estimate to the value of the estimate, expressed as a percentage. Lower RSE values are associated with higher levels of precision and, other things being equal, increases in sample size serve to reduce the RSE and thus increase the level of precision of the estimates. Estimates are considered unreliable and are suppressed in DAWN if their RSEs exceed 50 percent. Target RSEs for total episodes were 6 percent for the national estimates; 6 percent for the Chicago, Los Angeles, and New York metropolitan areas; and 8 percent for all other metropolitan areas. In 5 of the metropolitan areas (Baltimore, Buffalo, Denver, San Diego, and San Francisco), such a large proportion of facilities in each area would have been required to reduce the RSE to 8 percent that the decision was made simply to select all eligible hospitals. Figure 1 shows RSEs for total drug-related episodes by metropolitan area.

Once the sample size for each metropolitan area and the National Panel was determined, the number of sample units was allocated to the various strata based on the theory of optimal allocation. With this approach, strata with greater variability in drug-related episodes (from hospital to hospital) receive a proportionally larger number of sample units. Optimal allocation serves to reduce the RSE of the estimates for a given overall sample size or to enable a specified RSE to be achieved with a smaller sample, relative to proportional or random allocation to strata.

A total of 685 hospitals was selected for the new sample. Many of the facilities selected, particularly the larger ones, were already participating in DAWN. As noted earlier, 300 new hospitals had to be recruited. Recruitment started in April 1986 and proceeded in phases. By 1988, recruitment of the selected facilities was sufficiently complete to produce estimates based on the new sample.

Some facilities already participating in DAWN were not selected for the new sample. These facilities were retained in the system for sufficient time to obtain overlapping data for calibrating the estimates and developing estimation procedures for prior years. The period of overlap differed by metropolitan area but generally included the last quarter of 1988 and the first half of

1989. Most terminations of nonselected facilities were made in the second half of 1989 or in 1990.

The total number of eligible sample facilities has not remained at the original 685 because some hospitals have closed or become ineligible since the sample was selected while others have been added as part of sample maintenance. To preserve the integrity of the sample and ensure that the DAWN estimates will continue to be representative, sample maintenance is performed annually. Maintaining the sample involves updating the sampling frame with the most recent available information on the population of eligible hospitals. One purpose for updating the sampling frame is to identify newly eligible hospitals, or hospitals that are eligible and previously did not have a chance of selection, so that they can be sampled. A second purpose, which focuses on the estimation process, is to determine the population of eligible hospitals to which the estimates must apply, as well as the total number of ED visits among this population, which is used in the calculation of the analytical weights.

SAMPLING WEIGHTS

By 1988, hospital recruitment had progressed to a point where national estimates and estimates for each of the 21 metropolitan areas could be made with reasonable precision. National estimates are obtained by adding the estimates from the 21 metropolitan areas and the estimate from the National Panel for each estimation category.

The development of estimates from the sample data involves the application of analytical weights calculated on the basis of data from the sampling frame and from DAWN reporting records. Weights are calculated for each quarter of data using a 3-component model that considers:

- The base sampling weight calculated as the reciprocal of the sampling probability;
- An adjustment for nonresponse based either on complete nonparticipation or failure to provide data on all the reporting days in a given time period; and
- A correction (benchmark) factor, applied within metropolitan areas, that adjusts the total number of ED visits among participating sample hospitals to the total for the population of hospitals as determined from the sampling frame.

The estimation procedure was modified in 1989 to include the adjustments for 2 types of nonresponse and the ratio or benchmark adjustment based on ancillary data from AHA.

PRECISION OF THE ESTIMATES AND STANDARDS FOR PUBLICATION

Each estimate from the DAWN ED sample data is subject to sampling variability, which is the variation in the estimate that would be observed if different samples were drawn from the same population using the same procedures. The sampling variability of an estimate is measured by its standard error (SE) and relative standard error (RSE), which is defined as the SE expressed as a percentage of the value of the estimate. The precision of an estimate is inversely related to the degree of sampling variability as measured by the RSE; the greater the RSE value, the lower the precision.

If there are 10,000 estimated mentions of a given drug and this estimate has an SE of 500, then the RSE value is 5 percent. Therefore,

$$\text{RSE} = \text{SE}/\text{Estimate}$$

Confidence intervals (CIs) for estimates can be calculated using the corresponding RSE values published in these tables. If the sampling distribution for the estimate is normal, then the 95-percent CIs would be calculated as

$$\text{CI} = \text{Estimate} \pm 1.96 \times \text{RSE} \times \text{Estimate}$$

where 1.96 comes from the table of normal distribution z-values. Ninety-five percent of the normal distribution lies between the z-values of ± 1.96 .

Applying the formula in our example, the confidence limits would be as follows:

$$\begin{aligned} 10,000 \pm 1.96 \times 0.05 \times 10,000 &= 10,000 \pm 980.0 \\ \text{Lower limit: } 10,000 - 980 &= 9,020 \\ \text{Upper limit: } 10,000 + 980 &= 10,980 \\ \text{Confidence interval: } &9,020 \text{ to } 10,980 \end{aligned}$$

This means that if new samples were drawn from the same population of hospitals using the same sampling and data collection procedures, then the estimated total mentions of the drug in question would lie between 9,020 and 10,980 in 95 percent of the sample hospitals.

One simple rule is that in 68 percent of the episodes, estimates derived from repeated sampling would be expected to differ from the observed estimate by a percentage no more than the RSE value in either direction.

It is important to recognize when this CI formula should and should not be used. This formula can be used to calculate CIs around individual estimates, but some statistical comparisons between estimates (e.g., tests for differences across time) should not be made using this formula. For example, a reader might want to calculate CIs around 2 estimates and use those CIs to make a statistical comparison for which we did not publish a statistical test. (We publish only a fraction of the statistical tests that might be of interest.) However, the CI formula above may yield overlapping CIs even though the difference between the 2 estimates is statistically significant. This is because a comparison of 2 estimates must take into account not only the variance (var) of each estimate but also the covariance (cov) between the estimates as follows:

$$\text{var}(x - y) = \text{var}(x) + \text{var}(y) - 2\text{cov}(x,y)$$

Therefore, the above method for calculating CIs can be used only to compare independent estimates (i.e., where the covariance is zero). Whenever 2 estimates are not independent, as with ED episodes from 2 different years, their covariance must be taken into account.

The tests of statistical significance published in *ED Trends* account for the covariance between estimates from different years. From this, we know that the covariance between DAWN estimates is often sizable. Given the tremendous number of possible comparisons

between DAWN estimates, it is not possible to publish comprehensive covariance matrices at this time.

Examples of estimates, SEs, RSEs, and CIs are shown in Tables 1.6 and 1.8. RSE values for total episodes vary according to metropolitan area, not only because of differences in the target precision levels in the sample design, but also because of nonresponse. Table 1.8 shows data for estimates of mentions of the selected drug groups in the total coterminous U.S. As illustrated in this table, larger estimates tend to have lower RSE values, at least in the national estimates.

DAWN estimates with an RSE value of 50 percent or higher are regarded as too imprecise and are not published. With an RSE of 50 percent, the 95-percent CI for an estimate ranges from 2 percent to 198 percent of the estimate's value. In the tables, the symbol “...” is substituted for estimates that have an RSE of 50 percent or higher. The 3-dot symbol identifies cells in which the estimates do not meet the standard of precision required for publication.

Historically, estimates of less than 10 were not shown in the tables because we deemed them and their associated RSEs to be unreliable. Percentages corresponding to these numbers were shown or suppressed according to the same rules.

Beginning with the 1999 ED data, estimates of less than 10 are no longer suppressed in DAWN Detailed ED Tables or other ED publications. Many estimates as small as this will be suppressed by virtue of having RSEs greater than 50 percent. For those that are shown in the tables, we note for the reader that small numbers and their associated RSEs should be interpreted with caution.

Beginning with the 1999 ED and 1997 mortality data, we began suppressing small cells in selected tables to protect the confidentiality of individuals who are the subjects of these data. We will continue this practice for tables that involve detailed cross tabulations of patient and geographic characteristics.

PRELIMINARY VERSUS FINAL ESTIMATES

Final estimates are produced annually when all hospitals participating in DAWN have submitted their data for that year and when ancillary data used in estimation have become available. In recent years, the final publication has included separate final estimates for the first half and the second half of the year (quarterly estimates were produced in earlier years). In addition to the final estimates, preliminary estimates are also produced semi-annually based on responding hospitals. Data are weighted to produce national and metropolitan area estimates of ED drug-related mentions. The following factors clarify differences between preliminary and final estimates:

- Preliminary estimates may be based on less complete data than final estimates. Data from a small number of late-reporting hospitals are used in the production of final estimates. Data are continuously updated for a fixed time period. As such, final estimates usually have higher response rates.
- The DAWN sample is updated once annually, before the production of final estimates. Additional hospitals are added to the sample and incorporated into the final estimates for a given year (not the preliminary estimates for that same year). Most of these

hospitals are “newly eligible” because they became DAWN eligible sometime after the original sample was selected. The final DAWN estimates are produced after we receive the most current AHA Annual Survey of Hospitals file. This file is used initially to establish a sampling frame for DAWN. The most current AHA file is used once a year to maintain representativeness of the sample. Between the releases of the preliminary and final estimates, the use of the newer AHA survey can result in hospitals being added to the sample and incorporated into the final estimates.

- Data from the most current AHA file also are used to produce the final benchmark-adjusted weights.

ESTIMATES OF RATES PER 100,000 POPULATION

Rates of ED episodes or mentions per 100,000 population are generated using population data from the U.S. Bureau of the Census. The Office of Management and Budget (OMB) defines *Metropolitan Area* as the city core and its immediately adjacent geographic areas that are highly integrated economically and socially with the city core. Estimates of incidence rates are obtained by taking the estimates of total episodes and mentions for a given demographic category, dividing by the population estimate for that demographic category, and dividing by 100,000. These standardized measures provide the means for comparing drug abuse episodes and mentions across cities and over time. Semi-annual estimates are based on preliminary data from the first half of the year and are not comparable to annual estimates, which are based on 12 months of data.

Population estimates are derived from the following U.S. Census Bureau files:

- Civilian Noninstitutional Population of the United States by Age, Sex, and Race, which provides monthly population estimates by age, gender, race, and Hispanic origin for the total United States;
- Decennial Census Counts by Age, Sex, and Race, which provides population estimates by state and county, broken out by combinations of age, gender, race, and Hispanic origin; and
- County-Level Population Estimates, which provides estimates of annual total population by county as of July 1 of each year.

Population estimates¹⁹ are obtained by:

- Adjusting the annual County-Level Population Estimates to the Census Counts by Age, Sex, and Race to produce annual county demographic counts;
- Adjusting the annual county demographic counts to the Civilian Noninstitutional Population data to produce monthly county demographic counts; and
- Summing the monthly county demographic counts across all counties in the metropolitan area and across all months in the quarter (half year or year), to produce semi-annual or annual demographic counts for each DAWN area.

¹⁹ Table 1.9 shows population estimates by age and gender by metropolitan area.

Population estimates for 1994 through 2000 rely on 1990 Census data, and those beginning with 2001 use data from the 2000 Census. Inevitably, the accuracy of population estimates deteriorates over time relative to actual census counts. Population estimates for 2001, which are based on the 2000 Census, are considerably higher than population estimates generated for recent years. As a result, the incidence rates for 2001 may appear to have decreased significantly (or not to have increased as much as expected), but this may be an artifact of the increase in the population denominators for these rates. Changes in rate estimates between 2001 and prior years should be verified by comparing changes in the corresponding episode or mention estimates and their significance levels. If a statistically significant change in episode or mention estimates did not occur, it is likely that the statistically significant change in the rate was due to the changes in population.

REVISION OF ESTIMATION SYSTEM

In 1997 and 1998, a thorough review of the DAWN estimation system was undertaken by Westat. As a result of this review, the computer programs that compute the weighted estimates were rewritten to make them more accurate and efficient. While the methodology for computing weights did not change, errors were discovered in the prior programs that affected the estimates for 1995 and 1997. Final estimates for these 2 years were presented for the first time in *Mid-year 1998 Preliminary ED Data from DAWN*. The 1995 estimate of total drug-related episodes decreased by less than 1 percent (from 517,800 to 513,600) while the 1997 estimate increased by 5.5 percent (from 487,600 to 514,300). These changes had varying effects on the metropolitan area estimates.

The following changes had the greatest effect on the estimates:

- A change was made in the method for assigning eligibility status to a hospital. The current system tracks partial year eligibility, which improves the sensitivity of the DAWN nonresponse adjustment. Formerly, there was no recognition that a hospital could change its eligibility status during the year.
- A concerted effort was made to ascertain the current eligibility status of all nonparticipating DAWN sampled hospitals. Changes in status from eligible nonrespondent to ineligible (or vice versa) also affected the nonresponse adjustment.

APPENDIX C: SOURCES OF ERROR IN DAWN ESTIMATES

When producing estimates from any sample survey, 2 types of errors are possible—sampling and nonsampling errors. The sampling error of an estimate is the error caused by the selection of a sample instead of a census of hospitals. Sampling error is reduced by selecting a large sample or by using efficient sample design and estimation strategies such as stratification, optimal allocation, and ratio estimation. Nonsampling errors include nonresponse, difficulties in the interpretation of the collection form, coding errors, computer processing errors, errors in the sampling frame, and reporting errors.

Many procedures, such as data auditing and periodic retraining of data collectors, are used in DAWN data collection to minimize nonsampling errors. Moreover, nonrespondent hospitals are identified for additional recruitment. Late reporters are assigned for priority data collection and respondents with changes in reporting are designated for followup. Since data are abstracted from medical records completed by hospital staff who treated the patients, the accuracy of these reports depends on their careful recording of these conditions.

It is also important to recognize that DAWN does not provide a complete picture of problems associated with drug use, but rather focuses on the impact that these problems have on hospital EDs in the United States. If a patient is admitted to another part of the hospital for treatment, or treated in a physician's office or at a drug treatment center, the episode would not be included in DAWN.

CHANGES IN SAMPLE COMPOSITION AND REPORTING OF EPISODES

Periodic minor modifications are made to the sample to keep it current. Adjustments are made in the weights to account for lapses in reporting by the sampled hospitals. It is unlikely that modifications to the sample will affect estimates of the total drug, cocaine, and heroin mentions over time. Analyses of the previous changes in the sample composition have found them to have little impact on trends across several years.

It is important to consider the potential impact on DAWN trends from changes in the sample composition or reporting anomalies in key sample hospitals, particularly for metropolitan area data. Historically, DAWN analysts and field staff have attempted to identify and document such situations in the period before data release, and events that may have had a significant impact on the estimates were published in this section.

However, choosing the particular situations to highlight often involves more art than science, given that the actual impact on the estimates rarely has been known at the time of publication. This practice led us to question whether the situations that were being highlighted actually had the anticipated impact on DAWN estimates.

We analyzed some specific situations highlighted in recent DAWN publications to determine if those situations had the anticipated effect on DAWN estimates. These analyses have shown that generally, the types of situations published previously as limitations did not have the anticipated effects. Changes in small hospitals do not have a large impact on the estimates, and the DAWN estimation system already corrects for many nonsampling errors. Extensive

quality control measures have been implemented to investigate and address irregularities in the data prior to publication.

As a result of this analysis, we have concluded that listing inconsequential, nonsampling errors discredits the DAWN system unnecessarily and possibly contributes to misinterpretation of DAWN data. Therefore, we have decided to discontinue reporting data limitations unless the impact on the estimates is clear.

NOTEWORTHY SOURCES OF ERROR: ATLANTA DATA FOR 2001

We experienced significant missing data in Atlanta for 2001. Reliable Atlanta estimates could not be produced for January–June of 2001 because insufficient data were submitted by participating facilities for this period. The column of estimates for January–June 2001 have been suppressed and are indicated by “---” in tables for Atlanta in this publication and in tables published online. More Atlanta data were available for the second half of 2001, although missing data were still a concern.

The missing data from Atlanta also affects DAWN’s national estimates, which depend on estimates from the 21 metropolitan areas. The national estimate is equal to the sum of the metropolitan area estimates and the National Panel estimate. Therefore, we adopted an imputation approach to preserve the integrity of the national estimates. Imputation refers to the assignment of values to replace missing data and typically involves standard statistical methods and practices. In this case, the imputation used statistical models to determine what characteristics (e.g., drug mentions and patient demographics) the imputed episode records should contain. The statistical models used data submitted by all Atlanta hospitals prior to 2001 along with the available Atlanta data for 2001. As a conservative measure, we have also suppressed any Atlanta estimates for the second half July–December 2001 that were derived from more than 25 percent imputed data (also indicated by “---”). This suppression rule affected only a few Atlanta estimates for the second half of 2001 and none of the national estimates.

APPENDIX D: GLOSSARY OF TERMS

This glossary defines terms used by the Drug Abuse Warning Network (DAWN) in data collection activities, analyses, and publications. DAWN collects data and publishes findings separately for emergency departments (EDs) and death investigation jurisdictions. As a result, there are a number of terms that are unique to each component of DAWN.

This appendix is divided into 3 sections. The first section contains terms common to both the ED component and the mortality data component of DAWN. The second section focuses on terms specific to the DAWN ED system, while the third section focuses on terms specific to the mortality data system.

DEFINITIONS OF TERMS COMMON TO DAWN'S ED AND MORTALITY COMPONENTS

Drug abuse: The nonmedical use of a substance for any of the following reasons: psychic effect, dependence, or suicide attempt/gesture. In DAWN, nonmedical use means:

- The use of prescription drugs in a manner inconsistent with accepted medical practice;
- The use of over-the-counter drugs contrary to approved labeling; or
- The use of any substance (e.g., heroin, marijuana, peyote, glue, aerosols) for psychic effect, dependence, or suicide.

Drug category: A generic grouping of substances reported to DAWN, based on the classification of generic drugs by Multum Information Services. Multum Information Services is a subsidiary of the Cerner Corporation and a developer of clinical drug information systems and a drug knowledge base. More information is available at <http://www.multum.com>. The DAWN system has accumulated a vocabulary of thousands of substance names that have been mentioned in incidents of abuse. This vocabulary is updated monthly by the inclusion of new abuse substances and, through receipt of identifying information, the reclassification of drugs. Occasionally, this reclassification may result in a drug being shifted to a different drug grouping. The DAWN drug groupings are periodically reviewed in order to reflect the most recent changes in pharmaceutical classifications and drug legislation. Occasional changes in drug classification should be taken into consideration when comparing drug data from this publication with other DAWN publications. These classifications may involve street names and brand names, which are sometimes used to identify a substance and its generic drug group. Individual drugs comprising the most commonly reported drug categories can be found in Tables 2.3 to 2.7 of *Emergency Department Trends From DAWN*.

Additional clarification is provided for the following drug categories:

- *Alcohol-in-combination* – DAWN does not gather data on alcohol used alone, only alcohol used concomitantly with another abused substance. Therefore, all alcohol mentions are combination mentions.

- *All other substances not tabulated above (NTA)* – This category contains any substance reported to DAWN that could not be classified in other categories and has too few mentions to warrant being reported independently in DAWN tables. This category also includes certain terms that cannot be assigned reliably to any new category such as: (1) ambiguous, nonspecific terms that could fall into any of several categories (e.g., “AIDS medicine” could be an anti-infective, an anticonvulsant, or any number of other drugs); (2) undocumented, nonspecific terms (e.g., “thought organizer”); and (3) street terms for illicit substances that could not be linked reliably to a particular illicit substance (e.g., “T,” “butterflies”).
- *Amphetamines* – This class of substances has been extracted from the category of central nervous system (CNS) stimulants because of its importance as a major substance of abuse. For purposes of classification, “amphetamines” (plural) includes a class of compounds derived from or related to the drug amphetamine. Although some “designer” drugs fall into the class of amphetamines, we choose to report some of them individually as major substances of abuse (e.g., methamphetamine). This category does not include other CNS stimulants, such as caffeine or methylphenidate.
- *Club drugs* – During the 1990s, use of certain illicit drugs was linked to “raves” and dance clubs. These substances are commonly referred to as “club drugs.” When used in DAWN, the term club drugs includes Ketamine, flunitrazepam (Rohypnol), gamma-hydroxy butyrate (GHB, or its precursor, gamma butyrolactone [GBL]), and methylenedioxymethamphetamine (MDMA or Ecstasy). Although commonly used in the rave scene, methamphetamine and hallucinogens are classified separately from club drugs in DAWN.
- *Drug unknown* – “Drug unknown” may be recorded when drug abuse was known or suspected to have been involved, but the specific substance could not be determined. This includes 2 types of cases: those in which the drug was reported to DAWN as “unknown” and those in which drugs were reported to DAWN as “polysubstances.” For the purposes of DAWN, polysubstance refers to the abuse of more than one substance when the individual substances were not identified by the source record. Because DAWN cases are identified through retrospective medical chart review, there will always be cases in which the drug abuse was known but the particular substance was unknown or unknowable.
- *Heroin and Heroin/morphine* – This is the only drug classified differently in the ED and mortality components of DAWN. In the ED publications, heroin is classified as a major substance of abuse, separate from morphine, which is classified as a narcotic analgesic under CNS agents. In the mortality data publications, heroin and morphine are classified together in a single category. When heroin is ingested, it is metabolized to morphine, so that the toxicology testing commonly used in death investigations often does not distinguish between the 2. Therefore, a mention of either substance is recorded as heroin/morphine. A case mentioning both heroin and morphine will be “de-duplicated” and counted as a single heroin/morphine mention.
- *Illicit combinations* – This category includes compounds composed of 2 or more major substances of abuse that are mixed and taken together. For example, “speedball,” which usually refers to the combination of heroin and cocaine taken at once, would be classified as an illicit combination, whereas separate mentions of heroin and cocaine would be classified separately in the categories heroin and cocaine. Compounds

consisting of a major substance of abuse and another substance are classified in the category of the major substance (e.g., heroin with scopolamine is classified as heroin).

- **Inhalants** – This category includes anesthetic gases and psychoactive nonpharmaceutical substances for which the documented route of administration was inhaled, sniffed, or snorted. Psychoactive nonpharmaceuticals fall into one of the following 3 categories: (1) volatile solvents—adhesives (model airplane glue, rubber cement, household glue), aerosols (spray paint, hairspray, air freshener, deodorant, fabric protector), solvents and gases (nail polish remover, paint thinner, correction fluid and thinner, toxic markers, pure toluene, cigar lighter fluid, gasoline, carburetor cleaner, octane booster), cleaning agents (dry cleaning fluid, spot remover, degreaser), food products (vegetable cooking spray, dessert topping spray such as whipped cream, whippets), and gases (butane, propane, helium); (2) nitrites—amyl nitrites (“poppers,” “snappers”) and butyl nitrites (“rush,” “locker room,” “bolt,” “climax,” “video head cleaner”); or (3) chlorofluorohydrocarbons (freons). Anesthetic gases (e.g., nitrous oxide, ether, chloroform) are presumed to have been inhaled.
- **Major Substances of Abuse** – We use this term to refer to the most commonly abused drugs (e.g., alcohol-in-combination and cocaine) and those drugs that are typically referred to as “illicit.”
- **Other Substances of Abuse** – We use this term to refer to pharmaceutical agents not included in the Major Substances of Abuse.

Drug mention – This refers to a substance that was recorded (“mentioned”) in a DAWN case report. In addition to alcohol-in-combination, up to 4 substances (“mentions”) can be reported for each ED episode, and up to 6 substances can be reported for each drug abuse death. Therefore, the total number of drug mentions exceeds the total number of ED visits or deaths. Even when only one drug is mentioned, it should not be assumed that the substance was the sole and direct cause of the episode or death; allowances should be made for reportable drugs not mentioned or other contributory factors. (See also **Single-drug episode/death**.)

Metropolitan area: An area comprising a relatively large core city or cities and the adjacent geographic areas. Conceptually, these areas are integrated economic and social units with a large population nucleus. The current DAWN ED sample, which was redesigned in the 1980s, is based on the definitions of Metropolitan Statistical Areas (MSAs) and Primary Metropolitan Statistical Area (PMSAs) issued by the Office of Management and Budget (OMB) in 1983, with a few exceptions. Metropolitan areas represented in the DAWN mortality data system are consistent with those represented in the DAWN ED system, also with a few exceptions. Users of DAWN should note that the ED component provides estimates for each of the 21 metropolitan areas. However, in the mortality data component, only raw counts are provided, and in many instances less than 100 percent of the MSA is represented in those counts.

Not otherwise specified (NOS): Catch-all category for substances that are not specifically named in the listing. Terms are classified into an NOS category only when assignment to a more specific category is not possible based on information in the source documentation (ED patient charts and death investigation case files).

Not tabulated above (NTA): Designation used when categories are not presented in complete detail; smaller units are combined in the NTA category.

Race/ethnicity: Beginning in January 2000, the race and ethnicity categories collected on DAWN case report forms changed to match a change in the standard protocol issued by the OMB in 1997.²⁰ The new protocol permits separate reporting of race and Hispanic ethnicity; the ability to capture more than one race for an individual; modifications in nomenclature (e.g., “Black” was changed to “Black or African American”); division of certain categories (“Asian or Pacific Islander” was split into 2 categories, “Asian” and “Native Hawaiian or Other Pacific Islander”); and elimination of the “Other” category.

The race/ethnicity categories on the DAWN data collection forms are as follows:

Race

- *White* – A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
- *Black or African American* – A person having origins in any of the black racial groups of Africa.
- *American Indian or Alaska Native* – A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.
- *Asian* – A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.
- *Native Hawaiian or Other Pacific Islander* – A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.
- *Unknown* – Used when documentation of race is not available from source records.

Ethnicity

- *Hispanic or Latino* – A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.
- *Not Hispanic or Latino* – Ethnicity does not meet the definition of Hispanic or Latino.
- *Unknown* – Used when documentation of ethnicity is not available from source records.

Despite the increased detail allowed by the new categories, the actual race/ethnicity data reported to DAWN changed very little because race and ethnicity are often not documented with this level of specificity in patient/decedent records. As a result, we have retained the classification used previously to tabulate DAWN data. The one exception is that we now collapse the less commonly used categories into a category termed “Not tabulated above

²⁰ See Office of Management and Budget, *Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity*, *Federal Register*, 62 FR 58782, October 30, 1997.

(NTA)” instead of “Other.” Categories used to tabulate race and ethnicity data in the ED publications are:

- *White* – Anyone meeting the definition of white (above). Those who are identified as white and Hispanic are classified as Hispanic.
- *Black* – Anyone meeting the definition of black or African American (above). Those who are identified as black or African American and Hispanic are classified as Hispanic.
- *Hispanic* – Anyone whose ethnicity is Hispanic or Latino is placed in the category Hispanic, regardless of race.
- *Race/ethnicity NTA* – This includes those categories that are too small to report independently including: 2 or more races, American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander.
- *Unknown* – Race and ethnicity are unknown. Those who are identified only as Hispanic are classified as Hispanic.

In *Mortality Data from DAWN*, race/ethnicity data are tabulated as White, Black, Hispanic, and All others, where “All others” includes other reported races and ethnicities as well as unknown or missing data.

Route of drug administration: DAWN reporters are asked to record the method by which the substance was taken into the drug abuser’s body according to the following categories:

- *Oral* – Substance was ingested through the mouth (swallowed).
- *Injection* – Substance entered the body through a vein (intravenously), into the muscle (intramuscularly), or under the skin (subcutaneously).
- *Inhaled* – Gases or fumes of a substance were taken into the body by inhaling through the nose or mouth into the lungs (e.g., inhaling the fumes of glue, aerosols, paints, gasoline).
- *Smoked (includes freebase)* – Substance was consumed by smoking a cigarette, pipe, or similar device.
- *Sniffed/snorted* – Substance, acquired in a powder or crystalline form, was forcefully inhaled through the nose.
- *Other* – This category is used when the route of administration of the substance cannot logically be included as any of the above.

Readers should note that this information is often not documented in patient/decedent files and is therefore missing in DAWN tabulations. Caution should therefore be exercised in interpreting this information.

Single-drug episode/death: A single-drug episode or death is that in which only one drug was involved. Because multiple substances may be recorded for each DAWN case (see **Drug**

mention), readers should exercise caution in interpreting the relationship between a given drug and the number of associated ED visits or deaths. For example, if records for a given patient “mentioned” marijuana, this does not mean that marijuana was the only drug involved in the ED visit or that the marijuana caused the ED visit. One should always consider whether and how many other drugs were used in combination, but even then attributing a causal relationship between the visit and a particular drug may not be possible. Additionally, because alcohol is only documented if used in combination with another drug, DAWN cannot provide single-drug episode/death totals for alcohol.

DEFINITIONS OF TERMS FOR THE DAWN ED COMPONENT

Coterminous U.S.: The contiguous 48 States and Washington, DC; excludes Alaska and Hawaii. National estimates from DAWN refer only to the coterminous U.S.

Disposition of ED patient: Suggestions or recommendations made or actions taken by the hospital as they relate to the patient’s presenting problem:

- *Treated and released or referred* – The patient was given appropriate ED treatment and was released or, after appropriate ED treatment, the hospital referred the patient to another agency or to a private physician for additional services.
- *Admitted to hospital* – The patient was admitted as an inpatient to a hospital.
- *Left against medical advice* – The patient left the treatment setting without a physician’s approval.
- *Died* – The patient expired.

Drug abuse episode: A reported ED visit that involved drug abuse. Episodes involving patients under the age of 6 or over the age of 97 are not reported to the DAWN system. The number of ED patients in DAWN is not synonymous with the number of patients involved. One patient may make repeated visits to an ED or to several EDs, thus producing a number of episodes. It is impossible to determine the number of unique patients involved in the reported ED episodes because no patient identifiers are collected.

Drug concomitance: This term refers to whether a drug abuse episode involved a single drug (one mention) or multiple drugs (multiple mentions).

Drug use motive: DAWN classifies ED drug abuse episodes according to one or more of the following reasons for taking a substance(s):

- *Psychic effects* – A conscious action to use drugs to improve or enhance any physical, emotional, or social situation or condition. Two categories of psychic effect are:
 - Use of drugs for experimentation or to enhance a social situation (e.g., curiosity, peer pressure, “just wanted to know what it felt like,” “wanted to have fun,” “to get high,” “for kicks,” “to party”); and

- Use of drugs to improve or enhance any mental, emotional, or physical state (e.g., depression, anxiety, to relieve headache, reduce pain, stay awake, lose weight, relax, help study, get to sleep). Referred to in DAWN as “other psychic effects.”
- *Dependence* – A physiological or psychological condition characterized by a compulsion to take the drug on a continuous or periodic basis in order to experience its effects or to avoid the discomfort of its absence (e.g., had to take, had to have, needed a fix).
- *Suicide attempt or gesture* – Successful or unsuccessful action(s) taken for the purpose of self destruction or to gain attention.
- *Other reason* – Used when the reason for taking the substance cannot be classified into the categories above.

Estimate: A statistical estimate is the value of a parameter (such as the number of drug-related ED episodes) for the universe that is derived by applying sampling weights to data from a sample. DAWN produces representative statistical estimates for 21 metropolitan areas based on data from a sample of EDs in each of the 21 areas. An estimate for the coterminous U.S. is produced by summing estimates for the 21 metropolitan areas and an estimate for the National Panel.

Form in which drug was acquired: The form in which the substance was received by the user/abuser, not the form in which the substance was consumed. Categories are: tablet/capsule/pill, aerosol, liquid, powder/crystal, paper, pieces/chunks, injectable liquid, cigarette, plant material, unknown, and other. Readers should note that this information is often not documented in ED records and is therefore missing in DAWN tabulations. Caution should therefore be exercised in interpreting this information.

Hospital emergency department (ED): Only hospitals that meet eligibility criteria for DAWN are recruited to participate. To be eligible, hospitals must be non-Federal, short-stay, general medical and surgical facilities with EDs that are open 24 hours a day, 7 days a week, and located in the coterminous U.S. Specialty hospitals; hospital units of institutions; long-term care facilities; pediatric hospitals; hospitals operating part-time EDs; hospitals in Alaska and Hawaii; and hospitals operated by the Veterans Health Administration and the Indian Health Service are excluded.

National Panel: This term is used to denote 2 concepts relative to DAWN ED data: (1) The universe of eligible hospitals outside the 21 DAWN metropolitan areas but within the coterminous U.S. and (2) the sample of hospitals in DAWN that were selected from this universe. The National Panel sample is weighted to produce estimates for the National Panel universe. (See also **Metropolitan area**.)

p-value: The probability value is the actual probability associated with a statistical estimate; this is then compared with the significance level to determine whether that value is statistically significant. For a statistically significant result, the *p*-value must be less than or equal to the significance level. The traditional significance levels are *p* less than 0.001, 0.01, 0.05, and 0.10. A result with a *p*-value less than 0.05 is considered statistically significant in DAWN ED publications.

Population: See **Universe**.

Precision: The extent to which an estimate agrees with its mean value in repeated sampling. The precision of an estimate is measured inversely by its standard error (SE) or relative standard error (RSE). In DAWN publications, estimates with RSEs of 50 percent or higher are regarded as too imprecise to be published. ED table cells where such estimates would have appeared contain the symbol “...” (3 dots). (See also **Relative standard error**.)

Rank: A rank indicates the relative frequency of a measure, such as mentions for a particular drug category. For example, a drug category ranked second indicates that it accounted for the second highest number of mentions among all drug categories. When 2 or more drugs receive equal numbers of mentions, they are assigned the same rank. A difference in rank should be considered only as indicative of a difference in frequency among drugs reported to DAWN, regardless of the size of the difference. Such differences are not necessarily meaningful or statistically significant.

Reason for present ED contact: The reason for the patient’s visit to the ED, based on documentation provided in the medical record. Categories are:

- **Overdose/toxic ingestion** – Either intentional or accidental (e.g., effects of suicide attempt, coma). Anyone whose reason for contact is overdose is placed in this category, regardless of other reasons.
- **Unexpected reaction** – The drug’s effect was different than anticipated, thus causing concern (e.g., bad trip, panic, hallucinations).
- **Withdrawal** – Symptoms which occur when a patient stops taking a substance upon which he or she is physiologically dependent and suffers physical symptoms, including abdominal pain, cold sweat, hyperactivity, and tremors that require treatment.
- **Chronic effects** – Secondary conditions resulting from habitual use or dependence, including malnutrition, tetanus, blood poisoning, and so forth.
- **Seeking detoxification** – Patients with identified problems with chronic substance abuse who seek admission to a detoxification program and receive treatment from ED staff. This category was added to the data collection form in 1987. Some hospitals require patients to be processed in the ED prior to admission for detoxification. Caution should therefore be exercised in interpretation of this category and the remaining information.
- **Accident/injury** – Injuries resulting from accidents that were caused by or related to drug abuse. This category was added to the data collection form in 1987.
- **Other** – Reasons which cannot be classified into one of the aforementioned categories.

Reason for taking substance: See **Drug use motive**.

Relative standard error (RSE): A measure of the sampling variability or precision of an estimate defined as the estimate’s SE expressed as a percentage of the estimate’s value. For example, an estimate of 2,000 cocaine mentions with an SE of 200 mentions has an RSE of 10 percent. (See also **Precision** and **Standard error**.)

Sampling: Sampling is the process of selecting a proper subset of elements from the full population so that the subset can be used to make inference to the population as a whole. A probability sample is one in which each element has a known and positive chance (probability) of selection. A simple random sample is one in which each member has the same chance of selection. In DAWN, a sample of hospitals is selected in order to make inference to all hospitals; DAWN uses simple random sampling within strata.

Sampling frame: A list of units from which the ED sample is drawn. All members of the sampling frame have a probability of being selected. A sampling frame is constructed such that there is no duplication and each unit is identifiable. Ideally, the sampling frame and the universe are the same. The sampling frame for the DAWN hospital ED sample is derived from the American Hospital Association (AHA) Annual Survey of Hospitals.

Sampling unit: A member of a sample selected from a sampling frame. For the DAWN sample, the units are hospitals, and data are collected for all drug-related ED episodes at the responding hospitals selected for the sample.

Sampling weights: Numeric coefficients used to derive population estimates from a sample.

Source of substance: The immediate source of the substance that the patient abused is coded as follows:

- *Patient's own legal prescription* – This is coded only when the abuser was legally prescribed the drug of abuse. If one patient obtains a drug by legal prescription and sells it to another who abuses it, the source to the abuser is marked “street buy.” If the patient for whom the prescription was issued gives the drug to another patient who abuses it, the source to the abuse is “other unauthorized procurement.”
- *Street buy* – The drug abuser purchased a drug and/or prescription from a source other than legitimate channels.
- *Other unauthorized procurement* – The drug was acquired in a manner not consistent with accepted medical care but was not bought on the street. This category includes drugs purchased using forged prescriptions, stolen, or received as a gift.
- *Other* – Used when the source of the substance cannot logically be included as any of the above. This category includes all over-the-counter medications.
- *Unknown* – Reported when information on source was unavailable.

Readers should note that this information is often not documented in ED records and is therefore missing in DAWN tabulations. Caution should therefore be exercised in interpreting this information.

Standard error (SE): A measure of the sampling variability or precision of an estimate. The SE of an estimate is expressed in the same units as the estimate itself. For example, an estimate of 10,000 cocaine mentions with an SE of 500 indicates that the SE is 500 mentions.

Strata (plural), stratum (singular): Subgroups of a population within which separate ED samples are drawn. Stratification is used to increase the precision of estimates for a given

sample size, or, conversely, to reduce the sample size required to achieve the desired level of precision. The DAWN ED sample is stratified into 21 metropolitan area cells plus an additional cell for the National Panel. Then, within these cells strata are defined according to the annual number of ED visits, whether the hospital is located inside or outside the central city of the metropolitan area, and by the presence or absence of an organized outpatient department, alcohol/chemical dependence inpatient unit, or both. The strata are as follows:

Stratum	Annual ED visits	Location within metropolitan area	Outpatient department or alcohol/chemical dependence inpatient unit
In the 21 DAWN metropolitan areas:			
0	>80,000	Not applicable	Not applicable
1	<80,000	Central city	Both
2	<80,000	Central city	One only
3	<80,000	Central city	Neither
4	<80,000	Outside Central city	Both
5	<80,000	Outside Central city	One only
6	<80,000	Outside Central city	Neither
In the National Panel:			
0	>80,000	Not applicable	Not applicable
7	<80,000	Not applicable	Both
8	<80,000	Not applicable	One only
9	<80,000	Not applicable	Neither

Note: Stratum “0” is defined for each of the 21 metropolitan areas and the National Panel cells. See *Drug Abuse Warning Network Sample Design and Estimation Procedures: Technical Report*, November 1997.

Statistically significant: A difference between 2 estimates is said to be statistically significant if the value of the statistic used to test the difference is larger or smaller than would be expected by chance alone. For DAWN ED estimates, a difference is considered statistically significant if the *p*-value is less than 0.05. (See also ***p*-value**.)

Universe: The entire set of units for which generalizations are drawn. The universe for the DAWN ED sample is all non-Federal, short-stay, general medical and surgical hospitals in the coterminous U.S. with EDs open 24 hours a day, 7 days a week. (See also ***Coterminous U.S.***).

DEFINITIONS OF TERMS FOR THE DAWN MORTALITY COMPONENT

Cause of death: Cases are reportable to DAWN if the death investigation concludes that the death was either directly or indirectly caused by drug abuse. If a death was directly caused by drug abuse (e.g., a drug overdose), DAWN refers to the death as ***drug-induced***. If drug abuse was a contributing factor in the death, but not the immediate or sole cause, then DAWN refers to the death as ***drug-related***. It is important to note that DAWN data include both types of deaths. It is also important to note that a drug-induced death may involve more than a single drug. (See ***Single-drug episode***.)

Certified death: Any case accepted and reviewed by a medical examiner or coroner, who uses information from the death investigation to complete the death certificate.

Consistent panel: DAWN does not impute missing data for jurisdictions that have not reported for all or part of a given year. Therefore, tables and charts showing trends in deaths over time are based on a **consistent panel** of reporting jurisdictions. A consistent panel includes those jurisdictions that have reported data for at least 10 months of each year reflected in the trend table/chart. The reason for a consistent panel is to ensure that apparent changes over time are not a result of gaps in reporting. Because participating jurisdictions may change from year to year, consistent panels used in published reports will also change from year to year. This means that trends published in one annual publication are not necessarily comparable to trends published in subsequent annual publications.

Coroner: Death investigation jurisdictions typically use either a medical examiner system or a coroner system. Unlike medical examiners, coroners need not be physicians; usually the only prerequisite for serving as a coroner is that the individual be more than 18 years of age and a resident of the county or district to be served. Coroners are typically elected rather than appointed. They may have jurisdiction over counties or districts within states. (See also **Jurisdiction** and **Medical examiner**.)

Drug combinations: Published tables from the DAWN mortality data refer to “drug combinations” rather than “drug concomitance” (the term used in the ED component). This term refers to multiple drug mentions for a single death, and tables show particular combinations of substances reported for deaths. Readers should note that DAWN cannot differentiate between drugs actually *used* in combination (simultaneously) and drugs used sequentially.

Drug-induced death: A death directly resulting from drug abuse or other substance abuse, such as drug overdoses or the interactive effects of drug combinations. When more than one drug is mentioned, it cannot be determined which or whether one drug was the sole and direct cause of the episode or death.

Drug-related death: A death in which the abuse of a drug is a contributing factor, but is not the sole cause of death. Such cases include drug abuse that exacerbates a pre-existing *physiological condition*; drug abuse in combination with an *external physical event* (e.g., a fall or automobile accident); or a *medical disorder* that was itself caused by drug abuse (e.g., hepatitis contracted through injection drug use). Drug-related deaths are classified into 2 types, *confirmed* and *presumed*. The drug-relatedness is “confirmed” if documentation in the decedent’s file substantiates that conclusion. The drug-relatedness is “presumed” if the investigation suggests drug involvement, but the medical examiner/coroner has insufficient evidence to list drug abuse as a contributing cause on the death certificate. Both confirmed and presumed deaths are included in the published mortality data tables.

Jurisdiction: DAWN uses the term “jurisdiction” to mean the geographic area for which a medical examiner/coroner’s office is responsible. In many states, there is a 1:1 correspondence between jurisdictions and counties. In some states, there are multiple medical examiner/coroner offices within a given county, or there may be multiple counties covered by a “district” that includes one or more medical examiners/coroners. A few states are organized as a single statewide jurisdiction.

Understanding jurisdictions is important because this assists readers in interpreting aggregated data. Published DAWN mortality data are aggregated into metropolitan areas, which often comprise multiple jurisdictions. In some states, there are different death investigation procedures for different jurisdictions (most notably, some jurisdictions have medical examiner systems, while others have coroner systems). There are nearly always some differences in death investigation procedures across states (and notably, some metropolitan areas include jurisdictions in multiple states). Readers should be mindful of these variations when interpreting or comparing data.

Information on death investigation practices and an updated list of jurisdictions throughout the U.S. and Canada are available from the Centers for Disease Control and Prevention, Epidemiological Program Office at www.cdc.gov/epo/dphsi/mecisp/death_investigation.htm.

Manner of death: This variable is used to describe how the decedent died. It is applicable to both drug-induced and drug-related deaths. On the DAWN data collection form, manner of death is coded into the following categories:

- *Accidental/Unexpected* – Although the drug abuse was deliberate, the resulting death was unintended.
- *Suicide* – Death in which there is evidence that the decedent deliberately used drugs to bring about his or her demise.
- *Homicide* – Death in which the decedent’s life was taken by another individual by means of drugs. These cases, which do not involve the intentional abuse of drugs by the decedent, are not currently included in published tabulations of DAWN mortality data.
- *Natural* – Death was due to natural causes such as a medical disorder or disease process, if drug abuse caused or worsened the decedent’s condition.
- *Undetermined* – The manner of death cannot be determined from all available evidence.

In *Mortality Data from DAWN*, manner of death is collapsed into 3 categories: suicide, accidental/unexpected, and “all others.” The “all others” category includes cases for which manner of death was recorded as natural, unknown, or undetermined, and cases for which manner of death was missing.

Medical Examiner (ME): Death investigation jurisdictions typically use either a medical examiner system or a coroner system. Most medical examiners are licensed physicians or forensic pathologists, and are generally appointed (rather than elected). They may have jurisdiction over a county, district, or entire state. (See also **Coroner** and **Jurisdiction**.)

APPENDIX E: MULTUM LICENSE AGREEMENT

LEXICON LICENSE

Multum Lexicon¹

End-User License Agreement

1. INTRODUCTION

- A.** This License Agreement (the “License”) applies to the Multum Lexicon database (the “Database”). This License does not apply to any other products or services of Cerner Multum, Inc. (“Multum”). A “work based on the Database” means either the Database or any derivative work under copyright law; i.e., a work containing the Database or a substantial portion of it, either verbatim or with modifications. A translation of the Database is included without limitation in the term “modification.” Each end-user/licensee is addressed herein as “you”.
- B.** Your use of the Database acknowledges acceptance of these restrictions, disclaimers, and limitations. You expressly acknowledge and agree that Multum is not responsible for the results of your decisions resulting from the use of the Database, including, but not limited to, your choosing to seek or not to seek professional medical care, or from choosing or not choosing specific treatment based on the Database.
- C.** Every effort has been made to ensure that the information provided in the Database is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive.
- D.** Multum does not assume any responsibility for any aspect of healthcare administered or not administered with the aid of information the Database provides.

2. TERMS AND CONDITIONS FOR COPYING, DISTRIBUTION AND MODIFICATION

- A.** You may copy and distribute verbatim copies of the Database as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and give any other recipients of the Database a copy of this License (the readme.txt file) along with the Database and anything else that is part of the package, which should be identified.
- B.** You may modify your copy or copies of the Database or any portion of it to form a derivative work, and copy and distribute such modifications or work under the terms of Section 2.A. above, provided that you also meet all of these conditions:

¹ The Multum License Agreement can be found on the Internet at <http://www.multum.com>.

- i) You must cause the modified files to carry prominent notices stating that they are derived from the Multum Lexicon database from Cerner Multum, Inc. and that you changed the files and the date of any change(s).
 - ii) If you incorporate modified files into a computer program, you must cause it, when started running for interactive use in the most ordinary way, to print or display an announcement including an appropriate copyright notice, a notice that you have modified the Multum Lexicon database from Cerner Multum, Inc., and a notice that there is no warranty (or that you provide the warranty) and telling the user how to view a copy of this License.
- C.** It is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Database.
- D.** You may copy and distribute the Database (or a work based on it, under Section 2.B.) in an encoded form under the terms of Sections 2.A. and 2.B. above provided that you also do one of the following:
 - i) Accompany it with the complete corresponding machine-readable plain text, which must be distributed under the terms of Sections 2.A and 2.B. above on a medium customarily used for software interchange; or,
 - ii) Accompany it with a written offer to give any third party, for no charge, a complete machine-readable copy of the Database (and the entirety of your derivative work based on it, under Section 2.B.), to be distributed under the terms of Sections 2.A. and 2.B. above on a medium customarily used for software interchange.
- E.** You may not copy, modify, sublicense, or distribute the Database except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense or distribute the Database will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.
- F.** You are not required to accept this License. However, nothing else grants you permission to copy, modify or distribute the Database or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by copying, modifying or distributing the Database (or any work based on the Database), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Database or works based on it.
- G.** Each time you redistribute the Database (or any work based on the Database), the recipient automatically receives a license from Multum to copy, distribute or modify the Database subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties to this License.

3. DISCLAIMER OF WARRANTIES; LIMITATION OF DAMAGES

- A.** Because the database is licensed free of charge, there is no warranty for the program or data, to the extent permitted by applicable law. Except when otherwise stated in writing. Multum and/or other parties provide the database “as is” without warranty of any kind, either expressed, statutory or implied, including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the quality and performance of the database is with you. Should the database prove defective, incomplete, or inaccurate, you assume the responsibility and cost of all necessary servicing, repair or correction.
- B.** In no event (unless required by applicable law or agreed to in writing) will Multum, or any other party who may modify and/or redistribute the database as permitted above, be liable for any special, incidental, consequential, or indirect damages, including damages for loss of profits, loss of business, or down time, even if Multum or any other party has been advised of the possibility of such damages.
- C.** In addition, without limiting the foregoing, the database has been designed for use in the United States only and covers the drug products used in practice in the United States. Multum provides no clinical information or checks for drugs not available for sale in the United States and clinical practice patterns outside the United States may differ substantially from information supplied by the database. Multum does not warrant that uses outside the United States are appropriate.
- D.** You acknowledge that updates to the database are at the sole discretion of Multum. Multum makes no representations or warranties whatsoever, express or implied, with respect to the compatibility of the database, or future releases thereof, with any computer hardware or software, nor does Multum represent or warrant the continuity of the features or the facilities provided by or through the database as between various releases thereof.
- E.** Any warranties expressly provided herein do not apply if: (i) the end-user alters, mishandles or improperly uses, stores or installs all, or any part, of the database, (ii) the end-user uses, stores or installs the database on a computer system which fails to meet the specifications provided by Multum, or (iii) the breach of warranty arises out of or in connection with acts or omissions of persons other than Multum.

4. ASSUMPTION OF RISK, DISCLAIMER OF LIABILITY, INDEMNITY

- A.** The end-user assumes all risk for selection and use of the database and content provided thereon. Multum shall not be responsible for any errors, misstatements, inaccuracies or omissions regarding content delivered through the database or any delays in or interruptions of such delivery.
- B.** The end-user acknowledges that Multum: (a) has no control of or responsibility for the end-user’s use of the database or content provided thereon, (b) has no knowledge of the specific or unique circumstances under which the database or content provided thereon may be used by the end-user, (c) undertakes no obligation to supplement or update content of the database, and (d) has no liability to any person for any data or information input on the database by persons other than Multum.

- C. Multum shall not be liable to any person (including but not limited to the end-user and persons treated by or on behalf of the end-user) for, and the end-user agrees to indemnify and hold Multum harmless from any claims, lawsuits, proceedings, costs, attorneys' fees, damages or other losses (collectively, "losses") arising out of or relating to (a) the end-user's use of the database or content provided thereon or any equipment furnished in connection therewith and (b) any data or information input on the database by end-user, in all cases including but not limited to losses for tort, personal injury, medical malpractice or product liability.

5. MISCELLANEOUS

- A. You warrant that you have authority within the organization you identified during registration for the Database to enter into license agreements with other organizations including Multum.
- B. You agree that Multum may identify you and/or your organization by name as a "licensee", "licensed user", or "licensing organization" of the Database or a "client" of Multum in Multum's external market communications. You also agree that Multum may issue, if it desires, a press release stating that you and/or your organization have licensed the Database.
- C. If conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other obligations, then as a consequence you may not distribute the Database at all.
- D. If any portion of this License is held invalid or unenforceable under any particular circumstance, the balance of this License is intended to apply and the License as a whole is intended to apply in other circumstances.
- E. If the distribution and/or use of the Database is or becomes restricted in certain countries either by patents or by copyrighted interfaces, Multum may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

Multum Lexicon
Copyright (c) 1997, 1998, 1999, 2000, 2001
Cerner Multum, Inc.
3200 Cherry Creek South Drive, Suite 300
Denver, Colorado 80209

document revised November 30, 2000

Lexicon
Copyright © 2001 Multum Information Services, Inc.
3200 Cherry Creek South Drive, Suite 300
Denver CO 80209

(Sample Form Only)

**SELECTED REPORTING GUIDELINES AND INSTRUCTIONS
DRUG ABUSE WARNING NETWORK (DAWN)
EMERGENCY DEPARTMENT REPORT**

I. General

The following abbreviated guidelines and instructions highlight critical reporting items. Please refer to the detailed instructions found in the Instruction Manual for Emergency Departments for further information.

II. Reporting Guidelines

Report data on all patients seen in the emergency department for problems induced by or related to drug abuse. For DAWN, drug abuse is defined as the use of any illegal drug or the nonmedical use of a legal drug where the reason for taking the substance was for: psychic effects, dependence, or suicide attempt or gesture.

Detailed discussion of the "nonmedical" use definition and other case selection criteria can be found in Chapter II, Case Identification Guidelines, of the Instruction Manual for Emergency Departments.

III. Abbreviated Instructions for Completing Selected Items

Data Item #8 - Patient's Home Zip Code

Use "no fixed address" for the homeless (even if staying at a shelter) and for prisoners brought into the hospital.

Data Item #9 - Reason for Taking Substance(s)

The response categories are: Dependence, Suicide Attempt or Gesture, Psychic Effects: "Recreational Use," Other Psychic Effects, Unknown, and Other (Specify). The definitions are as follows:

1. *Dependence* - A physiological or psychological condition characterized by a compulsion to take the drug on a continuous or periodic basis in order to experience its effects or to avoid the discomfort of its absence (i.e., to avoid withdrawal).
2. *Suicide Attempt or Gesture* - Successful or unsuccessful action(s) taken for the purpose of self-destruction or to gain attention.
3. *Psychic Effects: "Recreational Use"* - Use of drug(s) for experimentation or to enhance social situations or conditions. Examples of common patient responses are: "just wanted to know what it felt like," "wanted to have fun," or "to get high."
4. *Other Psychic Effects* - Use of drug(s) to improve or enhance, any mental, emotional, or physical state. Examples of common patient responses concerning this self-applied medication are: "needed to relax," "wasn't feeling well," "to stay awake," "depression," "anxiety," "lose weight," "fight with a boyfriend/mate."
5. *Unknown* - Should be used only if information is unobtainable or unavailable.
6. *Other (Specify)* - Should be used only when the Reason for Taking the Substance cannot be classified into the categories above. Write the appropriate reason in the space provided.

Data Item #10 - Reason for Present Contact

This data item has two parts, A and B. Part A requires a selection of "YES" or "NO" to indicate whether the case is an Overdose / Toxic Ingestion. If the response to part A is "NO," part B requires a response.

3. *Chronic Effects* - Includes Hepatitis, Abscess, Cellulitis, Tremors, and AIDS contracted by IV drug abuse (see manual for additional examples).
8. *Non-Toxic Ingestion / Other (Specify)* - Should be used only when Reason for Present Contact cannot be classified into the categories above. (For example, police bring patient in for toxicological testing related to commission of a crime or parents force a child to come in to be checked because of strange behavior.) If Other, write reason in space provided.

Data Item #17 - Coded Remarks

Please be certain to write "HIV+" or "AIDS" in the first four blocks if the patient is a confirmed IV drug user.